Drug, bio-affecting and body treating compositions inventions 03/09

20090081119 - Inhibiting dna polymerase beta to enhance efficacy of anticancer agents: The invention provides anticancer methods. In one embodiment, the inventive method involves the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an inhibitor of DNA polymerase beta. In another embodiment, the invention provides anticancer methods involving the... Agent: Leydig Voit & Mayer, Ltd

20090081120 - Methods and compositions for increasing patient tolerability during myocardial imaging methods: The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A2A receptor agonists to a mammal undergoing myocardial imaging.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090081121 - Liposome compositions useful for tumor imaging and treatment: The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject.... Agent: Alston & Bird LLP

20090081122 - Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant: The injectable formulation for treatment by hyperthermia comprises a liquid carrier and heat-generating superparamagnetic iron oxide nanoparticles having a mean diameter not greater than 20 nm. Said injectable formulation is able to form in-situ a hyperthermic solid or semi-solid implant upon contact with a body fluid or tissue. Said hyperthermic... Agent: Harness, Dickey & Pierce, P.L.C

20090081123 - Pharmaceutical compounds: e

20090081124 - Virus coat protein/receptor chimeras and methods of use: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents... Agent: Moore & Van Allen PLLC

20090081125 - Angiogenetic agent containing adrenomedulin as the active ingredient: It is intended to provide an angiogenic agent which contains, as the active ingredient, at least one substance selected from the group consisting of adrenomedullin, a substance inhibiting the activity of adrenomedullin degrading enzyme, an adrenomedullin receptor activity-modifying protein, a calcitonin receptor-like receptor and an adrenomedullin receptor.... Agent: Reed Smith LLP

20090081127 - Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response: The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a... Agent: Edwards Angell Palmer & Dodge LLP

20090081128 - Model of alzheimer's disease: A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090081126 - Novel fully human anti-vap-1 monoclonal antibodies: Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090081130 - Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream: Microparticles are provided comprising a shell of an outer layer of a biologically compatible material and an inner layer of biodegradable polymer. The core of the microparticles contain a gas, liquid or solid for use in drug delivery or as a contrast agent for ultrasonic contrast imaging. The microparticles are... Agent: Dechert LLP

20090081129 - Bioluminescent endoscopy methods and compounds: Bioluminescent endoscopy methods and compounds, wherein an anatomical object is examined by means of filling, perfusing, intubating, injecting, or otherwise administering a solution containing a bioluminescent substance or a mixture of luciferin and luciferase which produces bioluminescence, wherein a color or monochrome image of the object is constituted using the... Agent: St. Onge Steward Johnston & Reens, LLC

20090081131 - Tumor therapy with high affinity laminin receptor-targeted vectors and compounds: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to... Agent: Darby & Darby P.C.

20090081132 - Water-borne aerosol composition: A water-borne aerosol composition containing an oil soluble insecticidal component (A), a hydrophobic organic solvent (B), water (C), a non-ionic surfactant (D) and a propellant (E), wherein the oil soluble component (A) is 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate and wherein the non-ionic surfactant (D) has a HLB in the range of 4.1 to... Agent: Birch Stewart Kolasch & Birch

20090081133 - Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations: Mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes,... Agent: Bucknam And Archer

20090081134 - Oral care compositions comprising tropolone compounds and essential oils and methods of using the same: The present invention relates to oral care compositions suitable for preventing or treating diseases or conditions of the oral cavity in warm-blooded animals including humans, comprising an oral care effective amount of at least one tropolone compound in combination with at least one essential oil, and a pharmaceutically acceptable oral... Agent: Philip S. Johnson Johnson & Johnson

20090081135 - Iodine-based oral antibacterial treatment methodology: An iodine-based oral antibacterial treatment methodology involves applying an effective amount of an iodine-based oral antibacterial treatment to the inside of a human or animal mouth in the gum area between the gum and a tooth wall. The delivered treatment includes available iodine, including molecular iodine, and an iodine free... Agent: Kenneth P. Glynn

20090081136 - Compositions useful for tooth whitening: The present invention provides tooth whitening compositions in the form of a liquid crystal or a microemulsion that includes a tooth whitening agent in an amount effective to whiten teeth, a hydrophilic phase including water, a hydrophobic phase including at least one oil, at least one anionic, nonionic, amphoteric or... Agent: Philip S. Johnson Johnson & Johnson

20090081140 - 6-methyl-4-(2',2',3'-trimethyl-3'-cyclopenten-1'-yl)-2-cyclohexen-1-ol as sandal odoriferous substance: to an odoriferous substance or aroma composition comprising such a compound, and to a perfumed or aromatized product comprising such a compound. The invention furthermore relates to the use of a compound of the formula (VII) as an odoriferous substance and/or for improving fixation of an odoriferous substance or aroma... Agent: Connolly Bove Lodge & Hutz LLP

20090081138 - Cancer chemoprotective compositions and natural oils and methods for making same: Cancer chemoprotective compositions containing reduced oil-content extraction meals made from plants containing natural oils and glucosinolates. The oil content of the extraction meals may be reduced using batchwise or continuous supercritical fluid extractions. Also provided are glucosinolate-rich compositions containing purified glucosinolates isolated from plant materials. The glucosinolate-rich compositions may be... Agent: Foley And Lardner LLP Suite 500

20090081137 - Crosslinked polytetrahydrofuran-containing polyurethanes: The invention relates to a cross-linked polyurethane, which contains, in an integrated manner, at least one polytetrahydrofuran and one polyisocyanate mixture, to cosmetic or pharmaceutical agents containing a polyurethane of the aforementioned type, and to the use of these polyurethanes.... Agent: Connolly Bove Lodge & Hutz, LLP

20090081141 - Topical use of thiazolidine derivatives against consequences of oxidative stress of skin: A cosmetic composition intended for protecting skin against stress generating free radicals or reactive oxygen species is disclosed. The cosmetic composition comprises a physiologically compatible excipient and a thiazolidine compound. Methods of protecting skin generally and against cutaneous consequences of oxidative stress are also disclosed.... Agent: Volpe And Koenig, P.C.

20090081139 - Water-based delivery systems: The invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor.... Agent: Reed Smith LLP

20090081142 - External preparation for skin: An external preparation for the skin containing isononyl 2-ethylhexanoate and/or 2-ethylhexyl 2-ethylhexanoate (i.e., component (a)); an oil-in-water emulsion type skin cosmetic composition containing the ingredient (a), (b) one or more ingredients selected from higher fatty acids and higher alcohols which are solid to semi-solid at an ordinary temperature (25° C.),... Agent: Foley And Lardner LLP Suite 500

20090081143 - Extracts from black yeast for whitening skin: The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme... Agent: The Estee Lauder Cos, Inc

20090081144 - Cosmetic compositions: A topical composition having (i) an isolated polypeptide having the sequence of SEQ ID NO: 1 or a functional equivalent thereof, and (ii) a cosmetically acceptable carrier; and use thereof.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090081146 - Hair dyeing composition: wherein n=1 or 2, R1 and R3 to R5 represent H, a hydroxy group, and an alkyl group with C12 or less optionally having a substituent, R2 represents a hydroxy group, —R or —OR, in which R means the same as R1 to R5, and two or more of R1... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090081145 - Process for forming disulphide bridges: The present invention relates to an improved method of formation of disulfide bridges in substances bearing SH groups, in particular peptides, for example by formation of intramolecular disulfide bridges, in which a heterocyclic compound having at least one nitrogen atom (e.g. caffeine or a caffeine-like substance) is used for catalysis... Agent: Henry M Feiereisen, LLC Henry M Feiereisen

20090081148 - Protection of keratinous fibers using ceramides and/or glycoceramides: The present invention relates to a composition for the protection of keratinous fibers containing at least one compound chosen from ceramides and glycoceramides, at least one cationic polymer, and at least one amphoteric polymer; to a process and kit for protecting keratinous fibers from damage caused by chemical treatment by... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090081147 - Permanent waving agent: e

20090081149 - Skin and hair care: A fermentation product of soya bean extract, e.g. soya milk, provides conditioning benefits for skin, particularly moisturising benefits, namely increased moisture, and conditioning benefits for hair, particularly reduction of fly away behaviour and improved curl retention.... Agent: Morgan Lewis & Bockius LLP

20090081150 - Cyclopropanated macrocyclic ketones and lactones: f

20090081151 - Olefin wax, silicone-modified olefin wax, silicone-modified room temperature-solidifying composition using the wax, and cosmetics using them: An olefin wax (A) is (i) a copolymer (A1) obtained by copolymerizing ethylene and at least one diene or a copolymer (A2) obtained by copolymerizing ethylene, at least one olefin selected from α-olefins of 3 to 12 carbon atoms and at least one diene; wherein (ii) the content of unsaturated... Agent: Buchanan, Ingersoll & Rooney PC

20090081152 - Antimicrobial compositions and methods of making same: This invention relates to a process of making a group of silylated poly(N-alkyl-4-vinylpyridinium) quaternized salts suitable for use as coating materials for the treatment of substrate surfaces to impart an antimicrobial effect.... Agent: Knobbe Martens Olson & Bear LLP

20090081153 - Combination of synthetic antimicrobial polymers and sesquiterpenoid compounds: The present invention provides compositions comprising a synthetic antimicrobial polymer and/or oligomer and a sesquiterpenoid compound useful in reducing the growth of microbes.... Agent: Pepper Hamilton LLP

20090081154 - Attractant composition for yellowjackets: Disclosed is a new attractant composition for yellowjacket wasps, which contains certain esters of butyric acid known to be attractive to yellowjackets, such as heptyl butyrate, octyl butyrate, or other esters of butyric acid, in combination with certain plant volatiles (kairomones), including trans-2-hexenol and methyl salicylate, said kairomones being used... Agent: William C. Hiscox

20090081155 - Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090081156 - Bioactive molecular matrix and methods of use in the treatment of disease: The composition may comprise one or more types of biomodulatory molecules selected from the group consisting of cytokines, bacterial molecules, receptor ligands, antigen binding fragments of antibodies, heat shock proteins, and integrins. The composition may further comprise one or more disease-specific antigens to stimulate an immune response. The disease-specific antigens... Agent: Wesley B. Ames

20090081159 - Compositions and methods for detecting and treating ophthalmic disorders: The present invention relates to compositions and methods for the detecting, treating, and conducting research on ophthalmic disorders associated with photoreceptor cell death and/or retinal insult. In particular, the present invention provides compositions and methods for increasing IL-6 expression and/or activity (e.g., exogenous IL-6), activating IL-6 receptors (e.g., IL-6R, sIL6-R),... Agent: Casimir Jones, S.c.

20090081157 - Immunostimulatory combinations for vaccine adjuvants: This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)” or “NLR” agonists, RIG-I-Like Helicase or “RLH” agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when... Agent: Dla Piper LLP (us)

20090081160 - Method for reducing the likelihood of implantation failure during an assisted reproduction in a subject: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Morris Manning Martin LLP

20090081158 - Phosphadiazine hcv polymerase inhibitors iv: Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV′, I″, II″, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Jones Day

20090081161 - Treatment of neoplasms with viruses: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to... Agent: Nixon & Vanderhye, PC

20090081163 - Cladribine regimen for treating multiple sclerosis: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090081162 - Method for downregulating an immune reaction: Ongoing pathogenic immune reactions and the severity of an incipient or prospective immune reaction may be downregulated or reduced by locally administering Type I interferon at a site remote from the ongoing, incipient or prospective immune reaction. The amount of interferon to be administered is that which is effective to... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090081165 - Bicyclic heteroaryl derivatives: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.... Agent: Genelabs Technologies, Inc. C/o Foley & Lardner LLP

20090081164 - Use of a cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said cyclosporin: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.... Agent: Richard Voellmy

20090081166 - Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria: Escherichia coli strains, such as enterotoxigenic E. coli strains, genetically engineered to express from recombinant plasmids one or more colonization factors (CFs) associated with enterotoxigenic Escherichia coli bacteria (ETEC) in an increased amount compared to said CFs expressed by ETEC wild-type reference strains, as well as a method of producing... Agent: Trask Britt

20090081171 - Cell system for alleviating syndromes of parkinson's disease in a mammal: A cell system for treating neurodegenerative disorders in a mammal is provided. The cell system includes a population of neurons differentiated from umbilical mesenchymal stem cells for expressing at least one of tyrosine hydroxylase (TH), dopamine-β-hydroxylase (DBH), glutamate decarboxylase (GAD), aromatic L-amino acid decarboxylase (AADC) and dopaminergic transporter (DAT) in... Agent: Panitch Schwarze Belisario & Nadel LLP

20090081172 - Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is... Agent: Leydig Voit & Mayer, Ltd

20090081167 - Folic acid producing bifidobaterium bacterial strains, formulations and use thereof: The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bifidobacterium, adolescentis species (2), the genus Bifidobacterium, breve species... Agent: Pearne & Gordon LLP

20090081173 - Methods and compositions involving bacteriophage isolates: Disclosed are methods of increasing the virulence of a bacteriophage, comprising contacting a bacteriophage with a composition comprising a bacterium or bacterial extract; and a polymer. Also disclosed are methods of propagating and isolating therapeutic bacteriophages that involve use of dilute polymer compositions. Also disclosed are pharmaceutical compositions the bacteriophage... Agent: Fulbright & Jaworski L.L.P.

20090081174 - Synergistic fungicidal compositions: Fungicidal compositions are described, consisting of mixtures comprising a copper (II) salt of phosphorous acid and at least another metallic salt of phosphorous acid or consisting of mixtures comprising a copper (II) salt of phosphorous acid, alone or mixed with at least another metallic salt of phosphorous acid, and one... Agent: Hedman & Costigan P.C.

20090081170 - Cardiac progenitor cells: The present invention relates to the field of progenitor cells, and in particular to the field of cardiac progenitor cells. More particularly, the present invention pertains to the identification of a population of progenitor cells in the adult mammalian heart that is capable of giving rise to significant levels of... Agent: Klauber & Jackson

20090081169 - Method for osteogenic differentiation of bone marrow stem cells (bmsc) and uses thereof: Methods for obtaining osteoprogenitors, osteoblasts or osteoblast phenotype cells, as well as cell populations including such cells, from human bone marrow stem cells in vitro or ex vivo are disclosed. Bone marrow stem cells are contacted with human serum or plasma and a growth factor or a biologically active variant... Agent: Knobbe Martens Olson & Bear LLP

20090081168 - Method of forming a peptide-receptor complex with zsig33: The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090081176 - Cure for the human immunodeficiency virus: A method whereby a cure is found for the Human Immunodeficiency Virus (HIV) by rebuilding and stimulating the infected individual's immune system.... Agent: Rudolph Maravich

20090081175 - Method for treating disseminated cancer: The present invention discloses an immunotherapeutic method for treating a patient suffering from a disseminated cancer by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more metastasis-draining lymph nodes (metinel nodes) draining a metastasis. The method comprises identification of one or more metinel lymph nodes in... Agent: Thorpe North & Western, LLP.

20090081179 - Method for reducing the severity of neurological disorders: e

20090081177 - Methods and compositions for improving pregnancy outcome: A method of increasing pregnancy rate in a female subject is provided, the female subject or an oocyte for introduction into the female subject being fertilized by a sperm from a male subject. The method includes the steps of administering to the male subject prior to fertilization: (i) an effective... Agent: Howson & Howson LLP

20090081178 - Phenolic binding peptides: The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide... Agent: Jennifer A. Haynes Genencor Division

20090081180 - Antimicrobial polymer conjugates: Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions.... Agent: Casimir Jones, S.c.

20090081181 - Isolation of growth and differentiating factors from colostrum: The present invention concerns a novel process for isolating growth and differentiating factors present in colostrum, all in a natural way. This process is characterized by maturation steps (controlled mild acid hydrolysis) and physical steps (molecular filtration) which optimize recovery of measured growth factors and their ability to entice a... Agent: Godfrey & Kahn S.c.

20090081182 - Modified lecithin-cholesterol acyltransferase enzymes: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.... Agent: Marshall, Gerstein & Borun LLP

20090081183 - Hiv transcription repressor complex and compositions and methods based thereon: The molecular mechanism of YY1/LSF-associated repression of HIV-1 is described herein. More particularly, an HIV transcription repressor complex containing YY1, LSF and HDAC1 is described. The invention is based on our discovery that (1) HDAC1 co-purifies with the LTR-binding YY1-LSF repressor complex; (2) the domain of YY1 that interacts with... Agent: Myers Bigel Sibley & Sajovec

20090081184 - Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain: This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdominal pain in a mammal. The methods include administering to... Agent: Lowrie, Lando & Anastasi, LLP

20090081185 - Apoptotic agents: A complex at least formed from at least one component A and at least one component B, wherein component A has a binding activity for cellular surface structures, and component B carries a protease or derivatives thereof as an effector function.... Agent: Jacobson Holman PLLC

20090081188 - Glycopegylated factor ix: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a... Agent: Morgan, Lewis & Bockius LLP (sf)

20090081186 - Methods and compositions for preventing and/or treating pancreatitis: The present invention relates to a method of preventing and/or treating pancreatitis in a subject, the method including administering to the subject a therapeutically effective amount of a Galanin antagonist and/or a Galanin receptor antagonist.... Agent: Townsend And Townsend And Crew, LLP

20090081187 - Pharmacological vitreolysis: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to,... Agent: Wilmerhale/boston

20090081191 - Antibodies that bind human 17-a1/epcam tumor antigen: The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions... Agent: Fulbright & Jaworski L.L.P.

20090081194 - Compositions and methods for reducing risk of development, or severity, of inappropriate immune response in eyes: A composition for reducing the risk of development, or severity, of an inappropriate immune response in an eye comprises an antagonist to at least a human TLR, an antagonist to at least a coreceptor of human TLR, a compound that is capable of inhibiting an activation of a human TLR... Agent: Bausch & Lomb Incorporated

20090081205 - Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents: The present invention provides effective dosing regimes for neural stem cell proliferating agents, kits containing effective dosing regimes for neural stem cell proliferating agents, and uses thereof. In particular, neural stem cell proliferating agents, such as hCG, prolactin and EPO are delivered to mammalian subjects at low doses in a... Agent: Fish & Richardson P.C.

20090081193 - Hemagglutinin polypeptides, and reagents and methods relating thereto: The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.... Agent: Choate, Hall & Stewart LLP

20090081198 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an... Agent: Keown & Zucchero, LLP

20090081202 - Immunogenic compositions and methods: Disclosed are immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating microbial infection, including, for example, influenza, or one or more symptoms thereof.... Agent: Haynes And Boone, LLPIPSection

20090081195 - Inhibitors of ste20-like kinase (slk) and methods of modulating cell cycle progression and cell motility: The invention provides inhibitors of Ste20-like kinase (SLK inhibitors). The inhibitors may be employed to modulate proliferation of cells, including tumor and cancer cells. The inhibitors also may be employed to inhibit motility or migration of cells, including cancer and tumor cells.... Agent: Suzannah K. Sundby Smith, Gambrell & Russel, LLP

20090081196 - Medicaments for fungal infections: The protein CAMP65p of C. albicans has been found to be play a significant role in both adhesion and the production of hyphae, which are important factors in both virulence and resistance to clearing. This invention provides antibodies to CAMP65p useful for administration to patients for prophylaxis and treatment of... Agent: Quine Intellectual Property Law Group, P.C.

20090081206 - Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals: A method and a pharmaceutical composition for inhibiting premature rapture of the fetal membranes, ripening of the uterine cervix and preterm labor of female mammals including human. The method includes the step of administering compounds for reversing at least two biochemical conditions being associated with the above processes. The pharmaceutical... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090081190 - Methods for antibody library screening: The present invention provides an improved method of screening a library of molecules to identify or select one or more members thereof which are candidate binding partners for one or more target entities: (a) contacting an expression library with one or more target entities; (b) subjecting said target entities to... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090081201 - Methods for identifying compounds for the treatment of type 1 diabetes: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090081197 - Methods for selection of melanocortin receptor-specific agents for treatment of obesity: Provided are methods for selecting melanocortin receptor-specific compounds for attenuating food intake and for treatment of specific disease conditions, including treatment of obesity and related energy homeostasis or feeding disorders characterized by excess weight gain, without inducing a sexual response, and methods for selecting compounds for treatment of sexual dysfunction.... Agent: Morgan Lewis & Bockius LLP

20090081203 - Methods for treating lymphomas in certain patient populations and screening patients for said therapy: Methods for predicting a response of a patient having a lymphoma to a therapy regimen of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione using prognostic factors of a patient's disease burden, absolute lymphocyte count or time since last rituximab therapy are disclosed. Specific methods of treating a lymphoma encompass the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione to a patient... Agent: Jones Day

20090081192 - Methods of screening for compounds having anti-inflammatory activity: A method screens compounds out of the group consisting of proteins, peptides, peptidomimetics, antibodies and small organic molecules that increase the activity of the protein Rac1 by virtue of their binding to the extracellular portion of this protein. The method includes the steps of: contacting a confluent layer of cultured... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090081199 - Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof: Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not... Agent: Foley And Lardner LLP Suite 500

20090081189 - Process for in vitro differentiation of neuronal stem cells or of cells derived from neuronal stem cells: v

20090081204 - Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits: The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits.... Agent: Darby & Darby P.C.

20090081200 - Tissue factor antibodies and uses thereof: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090081211 - C3b antibodies and methods for the prevention and treatment of complement-associated disorders: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090081214 - Genetic products differentially expressed in tumors and use thereof: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an... Agent: Mcandrews Held & Malloy, Ltd

20090081215 - Genetic products differentially expressed in tumors and use thereof: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an... Agent: Mcandrews Held & Malloy, Ltd

20090081207 - High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity: The present invention relates to recombinant human or humanized polypeptides which bind to α5β1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed.... Agent: Millen, White, Zelano & Branigan, P.C.

20090081213 - Methods and compositions for use in treatment of patients with autoantibody positive disease: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml... Agent: Leydig, Voit & Mayer Ltd.

20090081210 - Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells: The invention provides in vitro and in vivo methods of killing cancer cells, including therapeutic methods in humans, and also provides antibodies specific for the cancer specific antigen C35, and polynucleotides encoding such antibodies, as well as therapeutic and diagnostic methods of using such antibodies.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090081209 - Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins: Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with... Agent: Nuvelo, Inc

20090081208 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20090081216 - Treatment of pathologies which escape the immune response, using optimized antibodies: The invention relates to the use of potimised human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies having a strong affvinity for receptor CD16 of the effector cells of the immune system and being able to induce the secretion of cytokines and interleukins, in... Agent: Foley And Lardner LLP Suite 500

20090081212 - Use and targeting of cd98 light-chain proteins in therapies for thyroid hormone disorders: The invention is related to the normalization of thyroid hormone transport by modulation of 4F2hc, CD981c, and the 4F2hc-CD981c heterodimer. Approaches to identify compounds that modulate thyroid hormone disorders, methods of identifying agonists and antagonists that modulate thyroid hormone disorders, and methods of making pharmaceuticals that ameliorate a thyroid hormone... Agent: Knobbe, Martens, Olson & Bear, LLP

20090081218 - Fusion proteins: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20090081217 - Modified chimeric polypeptides with improved pharmacokinetic properties: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides... Agent: Regeneron Pharmaceuticals, Inc

20090081219 - Human monoclonal antibodies against cd25: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090081223 - Fixed dosing of her antibodies: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.... Agent: Genentech, Inc.

20090081220 - Method for diagnosing and treatment of breast cancer and pharmaceuticals composition and kit for same: Among other findings, the invention is based on the identification that p14 peptide is expressed in mammary carcinoma cells harboring MMTV. Thus, the invention provides methods for diagnosing breast cancer in subjects comprising determining the levels of expression of the peptide or the levels of anti-p14 antibodies produced in the... Agent: Nath & Associates

20090081221 - Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method: The present invention provides a novel method for inhibiting cancer cell metastasis using an antibody against TM7XN1, a pharmaceutical composition to be used for the method, and a cancer-metastasis-suppressing agent comprising an antibody against TM7XN1 as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20090081222 - Novel splice variants of the egf receptor: The present invention relates to a novel form of human EGFR found in certain tumors and conditions. The protein is termed here mLEEK, and the cDNA that encodes it has also been isolated. The mLEEK protein is capable of efficiently inducing the transcription of multiple genes resulting in various physiologic... Agent: Peters Verny , L.L.P.

20090081229 - Anti-pro87299 antibodies: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease... Agent: Genentech, Inc.

20090081224 - Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotheraphy: The invention relates to compositions of polypeptides specific to pathogenic strains comprising at least one polypeptide of a first group, having a sequence selected in the group comprising the sequences of SEQ ID No. 159, or homologous sequences of polypeptides of the first group and/or the second group with a... Agent: Nixon & Vanderhye, PC

20090081228 - Cyr61 compositions and methods: Polynucleotides encoding mammalian ECM signaling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signaling molecule coding sequence, or biological equivalents. Polypeptide compositions are... Agent: Howrey LLP - East

20090081227 - Human and mammalian stem cell-derived neuron survival factors: The present invention relates to human, rat and mouse stem cell-derived neuron survival factor polypeptides (SDNSF), a process for producing them, cDNA encoding SDNSF, a vector comprising the cDNA, host cells transformed by the vector, an antibody against SDNSF, pharmaceutical compositions containing SDNSF or the antibody, a method of assaying... Agent: Sughrue Mion, PLLC

20090081225 - Pif peptides biologic activities, site of action, and the antibody to detect pif: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing... Agent: Pepper Hamilton LLP

20090081226 - Soluble hla-e molecules and their use for diagnosing and treating pathologies: n

20090081230 - Human cytomegalovirus neutralising antibodies and use thereof: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B... Agent: Global Patent Group - Hmb Ms. Lavern Hall

20090081231 - Methods and compositions for use in treatment of patients with autoantibody positive disease: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml... Agent: Leydig, Voit & Mayer Ltd.

20090081232 - Methods of treating diseases with anti-vegf antibodies: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either... Agent: Genentech, Inc.

20090081234 - Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions: The present invention relates to novel anti-TNF antibodies for use in the treatment of depression, including therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20090081233 - Ligands that have binding specificity for vegf and/or egfr and methods of use therefor: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.... Agent: Mcdermott Will & Emery LLP

20090081235 - Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response: This invention provides methods of eliciting a secretory IgA-mediated immune response in a subject by administering a Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Compositions comprising secretory IgA antibodies that specifically recognize an epitope of HIV-1 also are provided.... Agent: Townsend And Townsend And Crew, LLP

20090081236 - Immunizing compositions and methods of use: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090081238 - Anti-notch1 nrr antibodies and methods using same: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.... Agent: Clark & Elbing LLP

20090081239 - Humanized pai-1 antibodies: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy... Agent: Wilson Sonsini Goodrich & Rosati

20090081237 - Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents: Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention identifies and characterizes the FANCI polypeptide as a vital component of the Fanconi anemia pathway and discloses inhibitors of FANCI and methods of using same. Such inhibitors are useful in inhibiting DNA damage repair... Agent: Edwards Angell Palmer & Dodge LLP

20090081240 - Human anti-kir antibodies: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090081241 - Anti-tnf antibodies, compositions, methods and uses: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF)... Agent: Philip S. Johnson Johnson & Johnson

20090081242 - Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a... Agent: Alston & Bird LLP

20090081243 - Agents and methods for diagnosing stress: The present invention discloses molecules and assays for qualitatively or quantitatively determining the effect of stress on the immune system, the susceptibility to developing disease or illness through immune system dysfunction as a result of stress, and for monitoring the ability of an animal to cope with stress. The invention... Agent: Proskauer Rose LLP

20090081245 - Assays for development of boris mutants suitable for vaccine development and small molecule inhibitors of wild-type boris: Disclosed are methods and compositions for developing mutants of the Brother of the Regulator of Imprinted Sites (BORIS) suitable for immunotherapeutic purposes. Said methods involve the mutagenesis and/or deletion of various sequences within wild-type BORIS protein with the objected aim of constructing nucleic acids and proteins encoded by said nucleic... Agent: The Law Office Of Jane K. Babin Professional Corporation

20090081244 - Dry formulation for transcutaneous immunization: A transcutaneous immunization system delivers antigen to immune cells through the skin, and induces an immune response in an animal or human. For example, skin-active adjuvant (e.g., an ADP-ribosylating exotoxin) can be used to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a dry... Agent: Morgan Lewis & Bockius LLP

20090081247 - Immune adjuvant comprising atp: This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising ATP or its pharmaceutically acceptable salt, its solvate, or its derivative having a physiological function... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090081246 - Method for isolating hepatitis c virus peptides: Described are methods for isolating Hepatitis C Virus peptides (HPs) that have a binding capacity to a MHC/HLA molecule or a complex comprising the HCV-peptide and the MHC/HLA molecule. In one aspect, these methods include providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule... Agent: Fulbright & Jaworski L.L.P.

20090081248 - Non-hemolytic llo fusion proteins and methods of utilizing same: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The... Agent: Pearl Cohen Zedek Latzer, LLP

20090081249 - Bi-functional polymer-attached inhibitors of influenza virus: Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir,... Agent: Pabst Patent Group LLP

20090081250 - Compositions and methods for treatment of cervical cancer: The present invention provides methods of treating, protecting against, and inducing immune response against cervical cancer, comprising the step of administering to a sub recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment a E7 and/or E6 antigen. The present invention also provides methods for inducing an... Agent: Pearl Cohen Zedek Latzer, LLP

20090081251 - Production of viral vaccines in suspension on avian embryonic derived stem cell lines: The present invention relates to the development and manufacturing of viral vaccines, particularly the industrial production of viral vectors and vaccines, and more particularly the use of avian embryonic stem cells, preferably the EBx cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses;... Agent: Buchanan, Ingersoll & Rooney PC

20090081253 - Composition: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against various diseases. In particular the invention relates to vaccine formulations comprising an oil-in-water emulsion adjuvant and 3D-MPL, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090081252 - Decreasing potential iatrogenic risks associated with influenza vaccines: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus 5 culture can increase... Agent: Novartis Vaccines And Diagnostics Inc.

20090081254 - Hiv vaccine for mucosal delivery: This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection.... Agent: Novartis Vaccines And Diagnostics Inc.

20090081255 - Method for producing the flu virus: i

20090081256 - Transgenic plant-based vaccines: A method of inducing partial or complete immunity to an infectious disease in a mammal comprising providing to the mammal for oral consumption an effective amount of a protein complex comprising five monomeric fusion proteins.... Agent: Sheldon Mak Rose & Anderson PC

20090081257 - Hydrogenase deficient bacterial strains: The present disclosure describes pathogenic bacteria that have been modified to be deficient in NiFe hydrogenase activity; compositions comprising such modified bacteria, and the use of such bacteria to protect animals from pathogenic enteric bacterial infections.... Agent: Bradford G Addison Barnes & Thornburg

20090081258 - Kennel cough vaccine: Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior... Agent: Hovey Williams LLP

20090081259 - 1-aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect: The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane.... Agent: The Firm Of Hueschen And Sage

20090081264 - Cleansing article: A cleansing article which is a sponge impregnated with cosmetic soap, in which encapsulated beneficial agents are embedded and methods for its manufacturing are provided. The shell of a capsule according to one preferred embodiment of the present invention is made of materials soluble in water such as capsules typically... Agent: Avia Kafri

20090081263 - Double-stranded rna oligonucleotides which inhibit tyrosinase expression: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 μm in size, having a zeta potential of from 10 to 80 mV.... Agent: Buchanan, Ingersoll & Rooney PC

20090081265 - Highly porous, recognitive polymer systems: The present invention includes compositions, methods, systems of making a composition that includes one or more active agent; a recognitive polymeric matrix; and a porosigen, wherein the composition comprises a porous recognitive, swellable hydrogel that dissociates under conditions of low water or humidity.... Agent: Chalker Flores, LLP

20090081261 - Liquid foundation, a makeup method, and a kit for implementing such a method: The present invention relates to a foundation including at least one coloring agent having non-zero magnetic susceptibility, the foundation presenting in bulk a hue angle h lying in the range 30° to 70° and lightness L* lying in the range 25 to 80, the coloring agent being selected in such... Agent: Oliff & Berridge, PLC

20090081262 - Metal oxide coating of water insoluble ingredients: The invention relates to process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid water-insoluble particulate matter with a cationic additive in an aqueous medium to obtain a dispersion of said particulate matter having a positive zeta potential; (b) coating the solid water-insoluble... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090081260 - Naturally resorbable polyacrylamide gel, production process and uses: A biodegradable polyacrylamide gel that is obtained from acrylamide monomers that are connected to one another by at least one amino acid includes at least one acryloylated amine or acryloylated amide group, or by at least one amino acid oligopeptide that comprises at least one acryloylated amine or acryloylated amide... Agent: Young & Thompson

20090081266 - Skincare mask packet: A skincare mask packet includes a packing bag, a skincare mask, and a skincare liquid packaging unit. An outer edge of the packing bag has a sealing function to form a packet configuration. In addition, the skincare mask is made of materials capable of absorbing liquid. An appropriate amount of... Agent: Hdls Patent & Trademark Services

20090081267 - Insect repellent fabric: An insect repellent fabric. The fabric comprises a fabric base and an active insect repellent ingredient. The active ingredient is contained within microcapsules and the fabric base is impregnated with the microcapsules. The preferred active ingredient is a Citronella extract or DEET.... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20090081268 - Antibacterial neck-tie: The neck-tie according to the present invention is made with an antibacterial yarn. This yarn presents intrinsic antibacterial properties and performs both a bacteriostatic and a bactericidal function. Said yarn is obtained by means of a procedure that entails adding, before the spinning phase, an antibacterial agent that comprises a... Agent: Sughrue Mion, PLLC

20090081269 - Control of fluid migration in wet-wipes: The present invention describes wet-wipe composition with a liquid portion that is impregnated in a substrate, wherein the liquid portion contains a binary pair of a thickening or gelling polymer along with a thickening or gelling agent which substantially reduces fluid migration of the liquid portion within a wet-wipes stack... Agent: Hercules Incorporated Hercules Plaza

20090081275 - Durable swellable hydrogel matrix and methods: The invention provides biocompatible polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a combination of linear and branched hydrophilic macromer compounds. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at... Agent: Kagan Binder, PLLC

20090081274 - Mast cell-derived renin: The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that... Agent: Schwegman, Lundberg & Woessner, P.A.

20090081273 - Medical devices and methods including polymers having biologically active agents therein: Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.... Agent: Medtronic, Inc.

20090081271 - Medical devices having a filter insert for controlled diffusion: An implantable or insertable medical device is provided which includes as components: (a) a substrate component comprising a depression that is at least partially filled with a therapeutic agent-containing material that comprises a first therapeutic agent, and (b) a pre-formed filter insert disposed in the depression such that it regulates... Agent: Mayer & Williams PC

20090081272 - Medical devices having a metal particulate composition for controlled diffusion: An implantable or insertable medical device is provided which includes as components: (a) a substrate component comprising a depression that is at least partially filled with a therapeutic agent-containing material that comprises a first therapeutic agent, and (b) a particulate composition disposed in the depression such that it regulates transport... Agent: Mayer & Williams PC

20090081270 - Biodegradable polyurethane and polyurethane ureas: This invention relates to biocompatible, biodegradable thermoplastic polyurethane or polyurethane/ureas comprising isocyanate, polyol and a conventional chain extender and/or a chain extender having a hydrolysable linking group and their use in tissue engineering and repair applications, particularly as stents and stent coating.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090081276 - Bioresorbable implant composition: A bioresorbable implant composition includes a polymeric macro- or micro-scaffold and first and second bioactive agents respectively incorporated on or within the polymeric macro- or micro-scaffold. The first and second bioactive agents modulate a different function and/or characteristic of a cell.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090081277 - Pharmaceutical formulations and methods for treating ocular conditions: Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit.... Agent: Allergan, Inc.

20090081278 - Drug delivery system: The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090081279 - Skin dressings: A skin dressing is adapted, on activation, to release one or more S-nitrosothiols, preferably S-nitroso-L-glutathione. S-nitrosothiols decompose spontaneously to produce nitric oxide, which has beneficial effects on tissues, particularly in wound healing.... Agent: Morgan Lewis & Bockius LLP

20090081280 - Compositions and methods for modulating hemostasis: Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090081282 - Pharmaceutical composition for treating cancer: The present invention provides a small interfering RNA (siRNA) that is capable of inhibiting intracellular expression of Wnt1 through complementary binding to a Wnt1 transcript (mRNA transcript) base sequence and a pharmaceutical composition for treating cancer comprising the same. siRNA of the present invention which is complementary to a base... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090081281 - Photosensitizer formulation for topical applications: Highly flexible penetrating liposomal carrier systems are formulated with enhanced skin penetration properties. These specialized formulations of highly flexible penetrating liposomal delivery systems comprise one or more phospholipids, lysophosphatides and hydrophobic photosensitizer. This new formulations can squeeze liposomal particles through intercellular regions of stratum corneum as intact structures, and, in... Agent: Bolesh J. Skutnik

20090081284 - Therapeutic agent for allergy containing liposome having oligosaccharide on its surface: g

20090081283 - Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to... Agent: Darby & Darby P.C.

20090081285 - Use of radical-capturing substances in a topical preparation for antipyretic treatment: e

20090081286 - Extended release venlafaxine formulation: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.... Agent: Hedman & Costigan P.C.

20090081287 - Pharmaceutical composition containing gelling agent: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Agent: Darby & Darby P.C.

20090081288 - Orodispersible domperidone tablets: The present invention relates to an orodispersible tablet comprised of, by weight: a maximum of 15% of a low-dose, therapeutically active substance; from 55% to 70% of mannitol of a particle size between 30 μm and 300 μm; at least 2% of maltodextrin; from 3.5% to 8% of croscarmellose sodium;... Agent: Birch Stewart Kolasch & Birch

20090081289 - Plant and a process for production of tablets: The invention relates to a plant for production of tablets, a process for production of tablets and tablets as such. The plant comprises a mixing device producing a mixed liquid feed of active pharmaceutical ingredient and excipients. A spray dryer atomizes the mixed liquid feed and dried particles with a... Agent: Sughrue Mion, PLLC

20090081291 - Sustained release dosage forms for delivery of agents to an oral cavity of a user: Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity of a user for the purpose... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090081290 - Tamper resistant dosage forms: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Agent: Darby & Darby P.C.

20090081292 - Oil-containing solid product and process for producing the same: An oil-containing solid in which liquid oil is contained in a large amount and from which oil seepage is slight; and a process for producing the same. The oil-containing solid is produced by impregnating a porous solid with a W/O emulsion. Further, use is made of the W/O emulsion having... Agent: Nixon & Vanderhye, PC

20090081293 - Sustained release of apo a-i mimetic peptides and methods of treatment: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090081295 - Nanoclusters for delivery of therapeutics: The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising... Agent: Holland & Hart, LLP

20090081294 - Sustained release dosage form for lubricating an oral cavity: Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity for the purpose of providing lubrication... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090081296 - Extracorporeal cell-based therapeutic device and delivery system: Extracorporeal cell-based therapeutic devices and delivery systems are disclosed which provide a method for therapeutic delivery of biologically active molecules produced by living cells in response to a dynamic physiologic environment. One embodiment includes long hollow fibers in which a layer of cells are grown within the intraluminal volume or... Agent: Goodwin Procter LLP Patent Administrator

20090081300 - Agent for use in the case of fructose intolerance: The present invention refers to an agent for use in the case of fructose intolerance and any form of impairment and affliction of health and well being which is caused by the administration of fructose or fructose containing foodstuffs or by the release of fructose in the digestive tract of... Agent: Heslin Rothenberg Farley & Mesiti PC

20090081301 - Microparticle dispersion liquid manufacturing method and microparticle dispersion liquid manufacturing apparatus: In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent. In a fixing step, the organic solvent, contained in a solution obtained in the dissolving step, is removed by evaporation, pellet-form residues 1 are obtained by the organic solvent removal, and... Agent: Drinker Biddle & Reath (dc)

20090081303 - Pharmaceutical formulation for contraception and hormone-replacement therapy: The present invention provides slow release estradiol-progesterone formulations that can be used in either contraception or hormone replacement therapies. The formulations comprise shaped particles of estradiol that is in a hemicrystalline form that exhibits especially low dissolution rates. The shaped particles comprise estradiol compounded in a 1:1 molar ratio with... Agent: Buchanan, Ingersoll & Rooney PC

20090081302 - Pulmonary delivery of polyene antifungal agents: The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections.... Agent: Nektar Therapeutics

20090081298 - Sustained release of apo a-i mimetic peptides and methods of treatment: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090081299 - Sustained release of apo a-i mimetic peptides and methods of treatment: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090081297 - Use of surface tension reducing agents in aerosol formulations: The present disclosure describes aerosol formulations that are particularly effective for pulmonary aerosol delivery. The aerosol formulations comprise an aqueous dispersion of active agent particles, said aqueous dispersion having an excess of a surface tension reducing agent. As a result of the reduced surface tension of the aqueous dispersion, the... Agent: Morrison & Foerster LLP

20090081304 - Composite pigment nanoparticles and processes to form organic-inorganic nanoparticle composite particles: Milling approaches provide for the efficient formation of composite particles having an inorganic nanoparticle core with an organic coating composition. The nanoparticles can additionally function as a milling media or distinct milling particles can be used and later separated from the product composite particles. In general, the milling is performed... Agent: Dardi & Associates, PLLC

20090081305 - Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents: Pharmaceutical compositions comprising liquid, nanostructures and pharmaceutical agents are provided. Methods of use such compositions are also provided.... Agent: Foley And Lardner LLP Suite 500

20090081306 - Microencapsulated materials and method of making same: A method of forming microspheres of a bioactive material, such as a protein polymer or drug by nebulizing a solubilized form of a material to be encapsulated and an encapsulating material, such as albumin, in a stirred chilled solvent system comprising a vegetable oil, mineral oil and/or a lower alcohol... Agent: Bryan Cave Powell Goldstein

20090081307 - Pesticidal composition: Since a pesticidal composition including a microcapsule formed by covering an oil containing a pesticidal active ingredient and an organic solvent with a wall material made of a thermosetting resin; at least one surfactant having a polyoxyethylene group in a molecule, selected from the group [A]: polyoxyethylene sorbitan fatty acid... Agent: Foley And Lardner LLP Suite 500

20090081308 - Anhdyrous lactose agglomerates and the preparation thereof: The invention relates to a process for the preparation of anhydrous lactose agglomerates, said process comprising (i) subjecting essentially anhydrous lactose primary particles comprising at least 60 wt % crystalline-lactose in a granulator to a wet granulation step at a temperature in the range of 30-100° C. using a binder... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090081309 - Stabilized oral suspension formulation: Orally deliverable pharmaceutical compositions are provided comprising a drug of tow water solubility suspended in an aqueous liquid vehicle comprising a wetting agent, a thixotropic thickening agent, and an inorganic suspending agent. The compositions are thixotropic, substantially deflocculated, and substantially physically stable.... Agent: Pharmacia Corporation Global Patent Department

20090081310 - Method for remediating a structure contaminated with mold: The invention provides methods for using chlorine dioxide gas (100) for the remediation of mold contaminated building spaces (400), heating ventilation and air conditioning systems, vehicles, office spaces, process equipment, files, documents, mail, mail processing equipment, industrial process equipment and consumer related items under safe conditions.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090081311 - Medium chain peroxycarboxylic acid compositions: The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.... Agent: Ecolab Inc.

20090081312 - Prevention and treatment of alveolar osteitis: A tissue adhesive antimicrobial material that is placed into a tooth extraction site for the sustained release of silver for the prevention and treatment of alveolar osteitis. The antimicrobial material is placed into a tooth extraction site via syringe, hand instrument or hand delivery device.... Agent: Merchant & Gould PC

20090081313 - Biodegradable magnesium alloys and uses thereof: Novel magnesium-based compositions-of-matter which can be used for manufacturing implantable medical devices such as orthopedic implants are disclosed. The compositions-of-matter can be used for constructing monolithic, porous and/or multilayered structures which are characterized by biocompatibility, mechanical properties and degradation rate that are highly suitable for medical applications. Articles, such as... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090081314 - Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors: There is disclosed a method for glycemic control of a patient having a disease selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, and postprandial hyperglycemia, said method comprising administering to a patient in need thereof a pharmaceutical composition comprising an... Agent: Jeffrey B. Oster

20090081315 - Iron composition containing milk protein: There are provided an iron composition including a milk protein and an iron preparation, which is stable in the presence of a substance having a property of releasing iron from the composition or reducing the released iron, and foods or drinks, animal feeds, and medicines blended with the iron composition.... Agent: Young & Thompson

20090081316 - Boron nitride-containing silicone gel composition: d) optionally, at least one component selected from the group consisting of other silicone, surfactant, emulsifier, solvent, emollient, moisturizer, humectant, pigment, colorant, fragrance, preservative, antioxidant, biocide, biostat, antiperspirant, exfoliant, hormone, enzyme, medicinal, vitamin substance, hydroxy acid, retinol, retinol derivative, niacinamide, skin lightening agent, salt, electrolyte, alcohol, polyol, ester, ultraviolet radiation... Agent: Dilworth & Barrese, LLP

20090081319 - Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal... Agent: Foley And Lardner LLP Suite 500

20090081317 - Microbiocidal control in the processing of meat-producing four-legged animals: Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise (I) contacting exterior surfaces of the live animal at least once when the animal is en route to being slaughtered but before it is killed by exsanguination, with a microbiocidal solution, or... Agent: Mcglinchey Stafford, PLLC Attn:IPGroup

20090081318 - Treatment of neuroads using inhibitors of glycogen synthase kinase (gsk)-3: Provided is a method of treating or preventing neurological disease in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a GSK-3 inhibitor.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090081320 - Method for weight reduction: The present invention relates to a method for weight reduction in a mammal, comprising a diet that either reduces or lifts the fat metabolism by glucose, combined with an intake of a composition that contains one or several active agents that promote fat burning.... Agent: Kratz, Quintos & Hanson, LLP

20090081321 - Therapeutic and cosmetic balsam: The invention relates to cosmetics and medicine and can be used for skin care or in form of a warming balsam. The present oily balsam represents a homogenous system and comprises a complex of the following oils, emollients and extracts: Macadamia oil, Bosvellia serrate extract (olibanum), isopropyl myristate, vegetable oil,... Agent: Borden Ladner Gervais LLP Gail C. Silver

20090081322 - Process for the preparation of antioxidant conserve from indian curry leaves (murraya koenigii spreng.): The present invention relates to a simple process for the preparation of safe, environmental friendly, and natural antioxidant conserve of activity ranging between 80-85%, comprising oleoresin from Indian curry leaves (Murraya Koenigii Spreng.), said process-comprising steps of drying the washed curry leaves at temperature ranging between 30-80° C., for time... Agent: John P. White, Esq. Cooper & Dunham, LLP

20090074658 - Compositions and methods for generating and screening adenoviral libraries: The present invention provides DNA libraries, libraries of viral clones and libraries of infectious viral particles and methods of generating and screening these libraries.... Agent: Edwards Angell Palmer & Dodge LLP

20090074657 - Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof: The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A... Agent: Venable LLP

20090074661 - Anti-il-22ra antibodies and binding partners and methods of using in inflammation: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention... Agent: Zymogenetics, Inc. Intellectual Property Department

20090074659 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20090074662 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090074660 - Human monoclonal antibodies to o8e: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Baker Botts L.L.P.

20090074664 - Cyclic azapeptides as integrin markers: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).... Agent: Siemens Corporation Intellectual Property Department

20090074663 - Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof: A peptide for diagnosing, preventing and treating atherosclerosis, and a use thereof, comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and a use thereof. The peptide effectively targets atherosclerotic plaques, and binds to IL-4R to thereby exhibit antagonistic effects on... Agent: Iphorgan, Ltd.

20090074665 - Diagnosis and treatment of cancer:i: A method of diagnosing cancer comprising the steps of (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining whether the sample contains a level of SCN5A (and optionally also SCN9A) voltage-gated Na+ channel nucleic acid or protein associated with cancer. A method of diagnosing... Agent: Nikolai & Mersereau, P.A.

20090074667 - Diagnostic methods for the detection of risk of neurodevelopmental disorders: The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD,... Agent: Townsend And Townsend And Crew, LLP

20090074666 - Peptide vaccine for influenza virus: The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The invention also provides peptide epitopes for use in the prevention and/or treatment... Agent: Birch Stewart Kolasch & Birch

20090074668 - Vldlr-/- mouse models and related methods: A Vldlr−/− mouse model and related methods has been shown to be an effective model for eye-disease studies and determination of effective therapeutics. Vldlr−/− mice are observed having both chorodial neovascularization coupled with subretinal deposits and photoreceptor atrophy. The mice of the present disclosure have knocked out the very low-density... Agent: Greenberg Traurig LLP (la)

20090074671 - Drug-immobilized inorganic nanoparticle: An object of the present invention is to provide a composite of an inorganic nanoparticle with a medicinal compound (i.e., an active substance), and to provide a method for producing the inorganic nanoparticle composite, which is highly versatile and convenient. The present invention provides an active substance-immobilized inorganic nanoparticle wherein... Agent: Sughrue Mion, PLLC

20090074670 - Hyperthermia therapeutic agent delivery system: A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials.... Agent: Akerman Senterfitt

20090074669 - Pnmt as a novel marker for progenitor cells: In certain aspects, the present invention provides methods and compositions relating to a Pnmt-positive progenitor cell. In certain aspects, the present invention relates to methods for isolating and transplanting the subject progenitor cells, and methods for treating diseases such as myocardiac injuries and neurodegenerative disorders.... Agent: Enrique G. Estevez

20090074673 - Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques: The disclosure provides, in part, compositions and methods for producing cellular labels for tracking cells by MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo.... Agent: Ropes & Gray LLP

20090074674 - Stabilized, biocompatible gold nanoparticles and enviro-friendly method for making same: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In methods of the... Agent: Greer, Burns & Crain

20090074672 - Tumor boundary imaging: Tumor boundaries and wound healing are optically imaged by cross-linking a fluorescently-labeled tissue transglutaminase substrate into extracellular matrix.... Agent: Richard Aron Osman

20090074675 - Indazoles as glucocorticoid receptor ligands: m

20090074676 - Inhibition of p38 mapk for treatment of obesity: The present invention is directed to the novel use of an inhibitor of CSBP/p38 Kinase for the treatment of obesity, and reducing weight loss in a mammal.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090074677 - Neuroactive steroid compositions and methods of use therefor: Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090074678 - Enzyme-containing candy: It is intended to improve a method of adding a non-thermostable enzyme to a candy base material. In the method of the invention, a non-thermostable enzyme is added to a candy base material, and the material is stirred so that a substantially uniform mixed dough-like mixture is obtained within 5... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20090074679 - Tooth whitening methods and apparatuses: Some disclosed tooth whitening methods comprise: painting a tooth whitening solution or gel including a bleaching agent onto teeth; and subsequent to the painting, disposing a conforming protective cover over the teeth. In some embodiments, the painting and disposing are performed under the non-interventional guidance of a session guide. In... Agent: Fay Sharpe LLP

20090074681 - Stabilized body care products, household products, textiles and fabrics: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain dialkylhydroxyamine stabilizers, dialkylhydroxylamine stabilizer salts, nitrone stabilizers or amine oxide stabilizers. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric... Agent: Joann Villamizar Ciba Corporation/patent Department

20090074680 - Statherin peptide and use in medicine: A synthetic statherin peptide of general formula (I) X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21 as defined herein is provided. The peptide finds application in the treatment of dent disease, dry mouth syndrome and in the formulation of pharmaceutical preparation comprising the peptide.... Agent: Pepper Hamilton LLP

20090074688 - Antimicrobial lotion compositions: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing... Agent: Bozicevic, Field & Francis LLP

20090074683 - Compositions and methods for treating keratinous substrates: The disclosure relates to compositions and methods of using the compositions to treat keratinous substrates. The compositions provide a water resistant and non-transferable protective barrier on the substrate. The compositions contain at least one polyamine, at least one acid, at least one water-insoluble ingredient, solvent and optionally at least one... Agent: Connolly Bove Lodge & Hutz LLP

20090074689 - Cosmetic composition comprising a volatile fatty phase: The invention relates to a composition comprising, in a physiologically acceptable medium, a volatile silicone fatty phase comprising at least one non-cyclic volatile silicone oil, wherein the volatile silicone fatty phase has an evaporation profile such that the mass of the at least one volatile silicone oil evaporated after 30... Agent: Thomas L. Irving Finnegan, Henderson, Farabow,

20090074687 - Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions: wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted... Agent: Marshall, Gerstein & Borun LLP

20090074686 - Novel inverse latices of copolymers of amps and of n,n-dimethylacrylamide; cosmetic use: Composition comprising an oil phase, an aqueous phase, at least one emulsifying system of water-in-oil (W/O) type, optionally at least one emulsifying system of oil-in-water (O/W) type, in the form of an inverse latex comprising from 20% to 70% by mass and preferably from 25% to 50% by mass of... Agent: Young & Thompson

20090074685 - Polyamide and emollient compositions, products made therefrom, and methods of making and using such compositions and products: Formulations comprising a polyamide and an emollient, wherein the emollient comprises at least one selected from the group consisting of hydrocarbons with more than 8 carbons that may be linear or branched, and saturated or unsaturated; esters, such as benzoate esters, simple esters, or bulky esters; glycerol or glycerol condensate... Agent: Arizona Chemical Company C/o Bo Segers

20090074682 - Silane esters and amides of 2-oxothiazolidine-4-carboxylic acid, and cosmetic uses thereof: The present invention relates to novel compounds of formula (1) and also to cosmetic compositions containing them and to the cosmetic uses thereof, in particular for protecting the skin against UV-induced oxidative stress.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074684 - Use of alpha olefin copolymers as photostabilizing agents in sunscreen compositions: The invention provides the use of an alpha olefin copolymer as a photostabilizing agent in a sunscreen composition comprising a dibenzoylmethane derivative UV-A absorbing agent, such as avobenzone. When alpha olefin copolymers are used said compositions preferably have a photostability decrease of less than about ⅓ of the photostability decrease... Agent: Philip S. Johnson Johnson & Johnson

20090074690 - Cosmetic compositions comprising at least one cationic copolymer and at least one triglyceride and methods of use thereof: e

20090074691 - Topical delivery system for antiaging and skin whitening agents: This invention relates to certain hydroxyaryl alkanols, alkyl amines, alkyl amino acids, alkyl amino esters, and alkyl amino alkanols (“Hydroxyaryl compounds”) of formula (I). A method of topical application of said hydroxyaryl compounds is also disclosed. The treatment of certain enzyme dysfunctions that cause skin or hair condition such as... Agent: Shyam K. Gupta Bioderm Research

20090074695 - Cosmetic compositions comprising at least one cationic copolymer, at least one amino silicone and at least one cationic polymer, and methods of use thereof: i

20090074701 - Methods of artificially coloring hair: The invention relates to methods of artificially coloring hair including applying to hair a composition containing at least one silicone film forming resin, at least one polysilicone polymer, and at least one hair colorant.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074702 - Methods of preserving artificial coloring on keratin materials: The invention relates to methods of preserving artificial color on keratin materials including applying to artificially colored keratin materials a composition containing at least one silicone film forming resin and at least one polysilicone polymer.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074696 - cosmetic composition comprising a cationic copolymer and a starch and cosmetic treatment process thereof: e

20090074697 - Use of monosaccharides and disaccharides as complete replacements for synthetic fixative and styling polymers in hair styling products: New hair styling compositions are described that use monosaccharides and/or disaccharides instead of synthetic fixative polymers or copolymers to provide excellent hold to hair without flaking.... Agent: Henkel Corporation

20090074699 - Cosmetic compositions comprising at least one cationic copolymer and at least one amino silicone and methods of use thereof: These compositions may be used for washing and/or conditioning keratin materials such as the hair or the skin.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090074698 - Cosmetic compositions containing at least one cationic copolymer, at least one cyclodextrin and at least one surfactant, and uses thereof: e

20090074700 - Compositions and methods for imparting shine onto hair: The disclosure relates to compositions and methods for imparting shine onto hair. The compositions provide a water resistant and non-transferable protective barrier on the substrate which protects the hair from adverse conditions and imparts shine. The composition contains at least one polyamine, at least one acid, at least one water-insoluble... Agent: Connolly Bove Lodge & Hutz LLP

20090074692 - Cosmetic composition comprising at least one cationic copolymer and at least one anionic associative polymer and cosmetic treatment processes using said composition: e

20090074693 - Temporary hair coloring composition and method of application: A method of temporarily altering the color of a person's hair to a desired color. First, a hair coloring mixture is prepared, which comprises a facial skin coloring powder, eyeshadow, and talc, wherein the facial skin coloring powder has a color substantially equivalent to the desired color. The hair coloring... Agent: Anthony R. Barkume

20090074694 - Dyed-hair-binding peptides and peptide-based hair reagents for personal care: Peptides have been identified that bind with high affinity to dyed hair. Peptide-based hair reagents formed by coupling a dyed-hair-binding peptide to a benefit agent are described. The peptide-based hair reagents include peptide-based hair conditioners and hair colorants. The peptide-based hair conditioners and hair colorants are comprised of a dyed-hair-binding... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090074703 - Animal bedding material: The present disclosure includes an animal bedding material comprising an aggregate of sized paper and corrugated material. The present disclosure also includes a method of generating animal bedding material comprising the steps of sizing paper, sizing corrugated material and aggregating the paper and the corrugated material.... Agent: Baker & Daniels LLP

20090074705 - Process for forming metal nanoparticles in polymers: A one step process is described for forming metal nanoparticles in polymers at atmospheric pressure and room temperature or with mild heating and stirring. The inventive process includes addition of nanoparticle precursor salts, e.g. HAuCl4 or AgNO3 into a “reducing” polymer resin, for example polyurethane resins, derivitized polyurethanes, polyurethane acyrlates... Agent: James M. Francis

20090074706 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers: o

20090074707 - Shaped body and method for production of said body: Water-dispersible or water-soluble polymers, particularly those of the family of compounds comprising the poloxamers or the polyesters or amphiphilic agents (emulsifiers), and also lipophilic materials are dispersed by melting the components at suitable temperatures with admixture of pharmaceutically active substances by mechanical procedures, i.e. a lipophilic dispers phase is distributed... Agent: Clark & Brody

20090074704 - Multi-arm polymer prodrugs: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The... Agent: Nektar Therapeutics

20090074708 - Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b): A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol,... Agent: Hdls Patent & Trademark Services

20090074709 - Methods, devices and systems for biocidal surface activity: A method of applying a biocidal polymer to a surface including applying a solution of the biocidal polymer to the surface, wherein the biocidal polymer includes biocidal groups and the biocidal polymer is insoluble in water. The biocidal groups can be selected from the group consisting of quaternary salt groups... Agent: Bartony & Hare, LLP

20090074716 - method for treating influenza virus infection: The invention concerns the treatment of orthomyxovirus infections with inhibitors of the ubiquitin protease system, in particular proteasome inhibitors.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074715 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090074713 - Dendritic cell tumor injection (dcti) therapy: The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with... Agent: Eckert Seamans Cherin & Mellott

20090074711 - Human therapies using chimeric agonistic anti-human cd40 antibody: Methods of human therapy using a chimeric anti-CD40 antibody, LOB 7/4 or humanized variants thereof, are provided. This CD40 antibody elicits agonistic effects on immunity when used as a monotherapy especially when used in the treatment of human lymphomas and leukemias and other solid tumors In addition, this agonistic CD40... Agent: Hunton & Williams LLP Intellectual Property Department

20090074714 - Method for treating urinary bladder cancer: The present invention discloses an immunotherapeutic method for treating a patient suffering from urinary bladder cancer by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a tumour in the bladder or a metastasis arising from a tumour in the... Agent: Thorpe North & Western, LLP.

20090074710 - Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine: The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof capable of binding to IL-18BP or a mutein, fused protein, functional derivative or fragment thereof and capable of inhibiting a receptor... Agent: David S. Resnick

20090074712 - Methods for treatment and prevention of infection: Specific cytokines may be used as agents for the treatment and/or prevention of bacterial infection, by binding to components of the bacterial cell membrane and directly killing the bacteria. This finding has a number of applications in screening methods, vaccine production and clearance of bacterial components.... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090074717 - Anti-viral compounds, compositions, and methods of use: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.... Agent: Genelabs Technologies, Inc./ Finnegan Henderson Farabow Garrett & Dunner, LLP

20090074718 - Avian derived erythropoietin: Erythropoietin obtained from eggs laid by transgenic avians having avian N-linked and O-linked glycosylation patterns.... Agent: Synageva Biopharma Corp.

20090074719 - Peptides, peptidomimetics and small molecule inhibitors of the epstein-barr virus mediated fusion and entry process: Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion.... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090074720 - Methods for decreasing immune response and treating immune conditions: The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which... Agent: Biotechnology Law Group C/o Portfolioip

20090074721 - Methods for treating viral infection with oral or injectibel drug solution: Pharmaceutical composition comprising compounds and/or compositions useful to inhibit viral replication are disclosed.... Agent: Pepper Hamilton LLP

20090074724 - Materials and methods for inhibiting wip1: Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or... Agent: Leydig, Voit & Mayer, Ltd.

20090074723 - Method of treating or retarding the development of blindness: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the... Agent: Howson And Howson

20090074722 - Products and methods for treating ptp lar diseases: The present invention relates to methods and products useful for the treatment of various epithelial cell migration diseases and disorders, and to methods useful for the identification of various products useful for the treatment of these diseases and disorders. In particular, methods for treating using PTP LAR are described, as... Agent: Foley And Lardner LLP Suite 500

20090074734 - Microbial intestinal delivery of obesity related peptides: Microbial delivery of obesity related peptides is disclosed. Genetically modified yeasts and/or lactic acid bacteria are described for the delivery of neuropeptides and/or peptide hormones that play a role in stimulation or inhibition of food intake and/or energy homeostasis.... Agent: Knobbe Martens Olson & Bear LLP

20090074733 - Thymidylate kinase mutants and uses thereof: c

20090074725 - Live organism product: A live organism product wherein the organisms are in a dormant state and are suspended in a liquid carrier which is sufficiently devoid of moisture so that the organisms will remain in a dormant state for several months. The carrier is comprised of oil. The carrier may also include an... Agent: Thomte Law Office, L.L.C.

20090074735 - Topical product containing sacrificial material for neutralizing free radicals: A topical product to protect the skin from free radicals is disclosed in one embodiment of the invention as including a carrier medium for topical application to the skin. A sacrificial material that is compatible with the skin is interspersed with the carrier medium. This sacrificial material may be selected... Agent: Ceramatec, Inc.

20090074726 - Mva expressing modified hiv envelope, gag, and pol genes: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.... Agent: Fish & Richardson PC

20090074728 - Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.... Agent: Cooper & Dunham, LLP

20090074731 - Method of isolation and use of cells derived from first trimester umbilical cord tissue: A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 20 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord... Agent: Borden Ladner Gervais LLP Anne Kinsman

20090074727 - Method of treating solid tumor: The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method.... Agent: Greenblum & Bernstein, P.L.C

20090074730 - Novel stem cells, nucleotide sequences and proteins therefrom: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.... Agent: Winston & Strawn LLP Patent Department

20090074732 - Scaffold for cell growth and differentiation: The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.... Agent: K&l Gates LLP

20090074736 - Implantable preparations comprising globin, process for their production, and uses: Preparations comprising, especially, globin that is insoluble at neutral pH, and therefore at physiological pH, in which the globin has been obtained from whole blood by depigmentation in a medium that extracts or dissolves the haem but leaves the globin and the other constituents of proteinic nature in a substantially... Agent: Stites & Harbison PLLC

20090074737 - Compositions and methods for prolonging survival of platelets: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to... Agent: Foley & Lardner LLP

20090074738 - 1-substituted-3-beta-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same: A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically... Agent: Sughrue Mion, PLLC

20090074739 - Pharmacological vitreolysis: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to,... Agent: Wilmerhale/boston

20090074740 - Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (rct): A method of determining a potential of a nondiabetic or diabetic patient to benefit from reverse cholesterol transport therapy for treatment of a vascular complication, followed by methods and compositions of treating the diagnosed vascular complications comprising determining a haptoglobin phenotype of the patient. Reverse cholesterol transport therapy includes inhibition... Agent: Pearl Cohen Zedek Latzer, LLP

20090074741 - Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic t lymphocyte response: Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.... Agent: Morrison & Foerster LLP

20090074743 - Inositol pyrophosphates determine exocytotic capacity: The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090074742 - Protein, osteoclast differentiation inhibitor, inflammatory bone resorption therapeutic agent, gene, recombinant vector, method of manufacturing a protein, method of inhibiting osteoclast differentiation, and method of treating inflammatory bone resorptio: There are provided a protein which comprises the amino acid sequence of an extracellular region of Ror2 and is water-soluble, an osteoclast differentiation inhibitor for inhibiting differentiation of a precursor cell of osteoclast into an osteoclast, which comprises the protein as described above, an inflammatory bone resorption therapeutic agent for... Agent: Ladas & Parry

20090074744 - Use of collagenase to facilitate guide wire crossing in total arterial occlusions: The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronic fibrotic occlusion, chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20090074729 - Augmentation and repair of spincter defects with cells including fibroblasts: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, PLLC

20090074746 - Compounds to treat alzheimer's disease:

20090074751 - Growth factor fraction compositions and methods: Compositions and formulations are provided comprising a growth factor fraction and at least one glucan. Also provided are methods for making the compositions and formulations. Methods of promoting growth in an animal using the compositions and/or formulations are also provided.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090074749 - Immunoglobulin g (igg) concentrate depleted of anti-a and anti-b antibodies and of polyreactive iggs: The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%,... Agent: Leyendecker & Lemire, LLC

20090074748 - Immunological control of beta-amyloid levels in vivo: Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a predetermined amide linkage are provided. The present invention also provides a vectorized antibody that is capable of crossing the blood brain barrier and... Agent: Wolf Greenfield & Sacks, P.C.

20090074747 - Methods and compositions for treating allergic diseases: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090074753 - Platelet-derived growth factor compositions and methods of use thereof: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and... Agent: Morrison & Foerster LLP

20090074750 - Regulator of basal cellular calcium concentration and methods of use: The invention features methods and compositions for determining states of basal intracellular calcium levels in a eukaryotic cell. Also provided are methods for identifying an agent (e.g., a gene product or small molecule compound) that modulates basal intracellular calcium levels (e.g., by modulating STIM-2 activity), as well as kits and... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090074752 - Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.... Agent: Baker Botts L.L.P.

20090074745 - Treatment and prevention of tissue damage: A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.... Agent: Frommer Lawrence & Haug

20090074754 - Methods and compositions useful in the treatment of mucositis: In certain aspects, the present invention provides compositions and methods for treating mucositis.... Agent: Ropes & Gray LLP

20090074757 - Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors: The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-homo- and α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and an antibody inhibiting a growth factor or its receptor, in the treatment of tumors. Also provided is the use of the said... Agent: Scully Scott Murphy & Presser, PC

20090074758 - Il-17 receptor a antigen binding proteins: The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.... Agent: Amgen Inc. Law Department

20090074765 - Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on... Agent: Nixon & Vanderhye, PC

20090074763 - Method for inhibiting bone resorption: The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more... Agent: Marshall, Gerstein & Borun LLP

20090074764 - Methods for diagnosing and treating neuroendocrine cancer: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090074766 - Methods of inhibiting hiv-2 infection: This invention provides methods of inhibiting HIV-2 infection of a susceptible cell by HIV-2 which comprises subjecting the susceptible cell to an effective HIV-2 infection inhibiting dose of a humanized antibody designated PRO 140, or of an anti-CCR5 receptor monoclonal antibody, wherein the effective HIV-1 infection inhibiting dose comprises from... Agent: Cooper & Dunham, LLP

20090074759 - Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof: Small animal models for assessing immunomodulatory effects of compounds are provided.... Agent: Ropes & Gray LLP

20090074761 - Therapeutic beta-glucan combinations: A therapeutic composition for treating a proliferative disorder includes a VEGF antagonist and β-glucan. VEGF is overexpressed in some tumor types. The efficacy of treatment with VEGF antagonists capable of activating complement in combination with β-glucan is significantly increased.... Agent: Biopolymer Engineering , Inc. Dba Biothera , Inc

20090074762 - Therapeutic use of anti-tweak receptor antibodies: Compositions and methods for treating solid tumors are provided herein.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20090074760 - Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20090074756 - Use of llt1 and/or cd161 for modulatting the activity of cells of the immune system: The present invention relates to a method for modulating in vivo or in vitro the activity of cells expressing CD161 and/or LLT1, characterized in that said cells are contacted respectively with LLT1 or fragments thereof, and/or with or fragments thereof.... Agent: Young & Thompson

20090074755 - Use of panton-valentine leukocidin for treating and preventing staphylococcus infections: The present invention relates to compositions and methods for treating Staphylococcus aureus (S. aureus) infections. In particular, the present invention provides vaccines comprising a Panton-Valentine Leukocidin (u) antigen, antibodies which bind a PVL antigen and compositions containing the same, methods of making such compositions and methods for treating S. aureus... Agent: Foley And Lardner LLP Suite 500

20090074768 - Activin-actriia antagonists and uses for treating or preventing breast cancer: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.... Agent: Ropes & Gray LLP

20090074769 - Glp-1 analog fusion proteins: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or... Agent: Eli Lilly & Company

20090074767 - Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phosphodiesterase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phosphodiesterase peptides, and methods of identifying... Agent: Celera

20090074770 - Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof: The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions,... Agent: Wolf Greenfield & Sacks, P.C.

20090074772 - Anti-cd70 antibody and its use for the treatment of cancer and immune disorders: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological... Agent: Townsend And Townsend And Crew LLP

20090074771 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses... Agent: Edell, Shapiro & Finnan, LLC

20090074773 - Cancer vaccine: The invention relates generally to the field of cancer diagnosis, prognosis, treatment and prevention. More particularly, the present invention relates to methods of diagnosing, treating and preventing lung cancer. In particular, aspects of the invention are directed to methods of diagnosing, treating and preventing small cell lung cancers. Methods of... Agent: Castellano PLLC

20090074783 - Babesia subtilisin: Provided is an isolated and purified protein produced by a naturally occurring Babesia sp. comprising an amino acid sequence at least 90% identical to SEQ ID NO:1 and an isolated and purified nucleic acid encoding the above protein. Additionally provided is an isolated and purified nucleic acid comprising at least... Agent: K&l Gates LLP

20090074782 - Compositions and methods for treating and diagnosing cancer: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090074778 - Connective tissue growth factor (ctgf-3): The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090074781 - Dengue virus peptide vaccine and methods of preparing and using the same: A consensus peptide sequence designed for domain III of the envelope proteins of four serotypes of dengue virus and used in a vaccine against multiple serotypes of dengue virus is disclosed. The vaccine is able to elicit cross-neutralization antibody responses against multiple serotypes of dengue virus.... Agent: Alston & Bird LLP

20090074774 - Fgfr binding peptides: The present invention relates to new peptide compounds capable of direct binding to fibroblast growth factor receptor (FGFR) and activating said receptor. The compounds of the invention comprise peptide fragments of the neural cell adhesion molecule (NCAM) derived from the fibronectin type-III module 1 (F3, 1) of NCAM. Peptide sequences... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090074776 - Human fgf-21 gene and gene expression products: This invention relates to human fibroblast growth factor (hF-GF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods... Agent: Davis Wright Tremaine, LLP/seattle

20090074780 - Methods of modifying antibodies, and modified antibodies with improved functional properties: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of immunobinders, and in particular of single chain antibodies (scFvs), including such properties as stability, solubility, and/or antigen binding affinity. The invention provides methods of engineering immunobinders, and in... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090074779 - Neurotrophin-derived peptide sequences: The present invention relates to peptide sequences capable of stimulating neuronal cell differentiation, neural cell survival and neuronal plasticity associated with memory and learning. The peptide sequences of the invention are derived from the proteins belonging to neurotrophic factors, such as NGF, NT3, NT4/5 and BDNF. The invention also relates... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090074775 - Use of anti-ab antibody to treat traumatic brain injury: A method of effectively treating traumatic brain injury is described. The method comprises administering an effective amount of an anti-Aβ antibody to a living mammalian biosystem such as to a human. An antibody useful in such treating includes an antibody that therapeutically attenuates the toxic effects of the Aβ peptide... Agent: Patrick W. Rasche (15060) Armstrong Teasdale, LLP

20090074777 - Wnt proteins and detection and treatment of cancer: The present specification provides, inter alia, methods of using Wnt and FZD proteins, genes, FZD and Wnt-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver cancer.... Agent: Fish & Richardson PC

20090074785 - Compositions and methods for treatment of colorectal cancer: We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with... Agent: Biotechnology Law Group C/o Portfolioip

20090074786 - Formulations for treating ocular diseases and conditions: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but... Agent: Morrison & Foerster LLP

20090074784 - Treatment of chronic viral diseases with antibodies to costimulating polypeptide of t cells: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or... Agent: Jones Day

20090074787 - Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer: The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also referred to as 11.2.1 or CP-675,206), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also referred to as 10D1... Agent: Pfizer Inc

20090074788 - Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved: The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying... Agent: Hunton & Williams LLP Intellectual Property Department

20090074789 - Compositions and methods for treating ocular diseases and conditions: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive... Agent: Biotechnology Law Group C/o Portfolioip

20090074790 - Methods for measuring transforming growth factor beta (tgf-beta) receptor signaling activity and uses thereof: Methods are disclosed for determining the optimal biologic dose of a TGFβ receptor kinase inhibitor for administration to patients in need of such therapy and for monitoring the effectiveness of therapy with a TGFβ receptor kinase inhibitor in patients receiving such therapy. Kits comprising antibodies and reagents useful in such... Agent: Klauber & Jackson

20090074791 - Phenylisoquinoline and phenylquinazoline derivatives: The present invention relates to substituted phenylisoquinoline and phenylquinazoline derivatives and to their pharmaceutical uses in preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090074792 - Compositions containing full-length l1r nucleic acid and endoplasmic reticulum-targeting sequence, and methods of use: The invention described here encompasses DNA and protein vaccines against poxviruses, and relevant immunogenic compositions, comprising at a minimum a nucleic acid encoding a modified full-length poxvirus L1R gene or its ortholog. The L1R gene is modified so that an endoplasmic reticulum-targeting sequence is operably linked on the 5′ end.... Agent: U.s. Army Medical Research And Materiel Command Attn: Mcmr-za-j (ms. Elizabeth Arwine)

20090074794 - Anti-tnf antibodies, compositions, methods and uses: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis... Agent: Philip S. Johnson Johnson & Johnson

20090074793 - High affinity human antibodies to human il-4 receptor: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.... Agent: Regeneron Pharmaceuticals, Inc

20090074795 - Methods for addressing ocular diseases through interference with the wnt signaling pathway: Choroidal neovascularization (CNV) in age-related macular degeneration (AMD) is a leading cause of blindness. Very low-density lipoprotein receptor gene knockout (Vldlr−/−) mice have been shown to develop subretinal neovascularization (NV) with an unknown mechanism. The present disclosure presents novel methods for addressing eye-disease states characterized by angiogenesis or neovascularization by... Agent: Greenberg Traurig LLP (la)

20090074797 - Novel gene upregulated in cancers of the prostate: The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.... Agent: Agensys C/o Morrison & Foerster LLP

20090074796 - Pde5 inhibitor compositions and methods for immunotherapy: The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20090074798 - System and method for the production of recombinant glycosylated proteins in a prokaryotic host: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains... Agent: Covington & Burling, LLP Attn: Patent Docketing

20090074799 - Antibodies to class ii cytokine receptor-7: Antibodies to novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in kidneys, pancreas, prostate, adrenal cortex and nervous tissue. The polypeptides may be used within methods for detecting ligands that promote... Agent: Zymogenetics, Inc. Intellectual Property Department

20090074800 - Cancer antigen and use thereof: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an... Agent: Greenblum & Bernstein, P.L.C

20090074801 - Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p 7: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for the treatment of sensitized allergic patients and for prophylactic vaccination.... Agent: Smith Patent Consulting Consulting, LLC

20090074802 - Immunomodulating oligopeptides: The invention provides immunomodulating peptides of the general formula X—P—Y, preferably I—P—Y, and/or oligopeptides comprising this amino acid sequence and/or conjugates with these peptides. Also provided are pharmaceutical compositions with these peptides and conjugates.... Agent: Banner & Witcoff, Ltd.

20090074803 - Immunogen platform: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including,... Agent: Knobbe Martens Olson & Bear LLP

20090074804 - Vero cell-based influenza virus strains and vaccines: The present invention relates to isolated influenza virus strains suitable for increased vaccine production for mammals. The influenza virus strains contain at least one modified influenza protein that results in increased production of the influenza virus from a mammalian host cell, such as a vero cell. The present invention also... Agent: Alston & Bird LLP

20090074805 - Yeast-based therapeutic for chronic hepatitis c infection: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with... Agent: Sheridan Ross P.C.

20090074807 - Moraxella (branhamella) catarrhalis antigens: The present invention relates to polypeptides of Moraxella (Branhamella) catarrhalis which may be useful for prophylaxis, diagnostic and/or therapy purposes.... Agent: Seed Intellectual Property Law Group PLLC

20090074806 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Mr. Reza Yacoob Aventis Pasteur Limited

20090074808 - Secreted streptococcus pneumoniae proteins: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090074809 - Composition of entomopathogenic fungus and method of production and application for insect control: Microsclerotia of entomopathogenic fungi, including Metarhizium species, Beauveria species, and Lecanicillium species, may be produced. These microsclerotia are effective for the control of a wide variety of insect pests, particularly soil-dwelling insect pests.... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20090074810 - Modified adenovirus hexon protein and uses thereof: The present invention provides a method of altering the specificity of an adenovirus vector. The method involves providing an adenovirus having a capsid with a modified adenovirus hexon protein. The modified adenovirus has a capsid comprising a hexon protein with a deletion in hypervariable region 1 and/or hypervariable region 4... Agent: Howson And Howson

20090074811 - Kennel cough vaccine: Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior... Agent: Hovey Williams LLP

20090074812 - Influenza m2 protein mutant viruses as live influenza attenuated vaccines: A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090074813 - Compositions and methods using variant tat proteins: The present invention relates to methods to activate peripheral blood mononuclear cells. The present invention further provides methods for the identification of blocking agents of Tat protein activation of PBMCs and for identifying an active portion of a Tat polypeptide for incorporation as an immunogen in a vaccine. The present... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20090074814 - Dna vaccines encoding antigen linked to a domain that binds cd40: Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto... Agent: Marshall, Gerstein & Borun LLP (trubion)

20090074815 - Immunomodulator compounds as vaccine enhancers: A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090074816 - Tissue targeted antigenic activation of the immune response to cancers: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate... Agent: Bozicevic, Field & Francis LLP

20090074817 - Type iii secretion pathway in aeromonas salmonicida, and uses therefor: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090074818 - Composition comprising parasite eggs and methods for isolation and storage of parasite eggs: The invention relates to a composition for storage and development of eggs from helminthic parasites, where the composition further comprises a liquid carrier having a pH value of below 7 at a temperature of from 1° C. to ambient temperature. The liquid carrier can be sulphuric acid, H2SO4 with a... Agent: Crockett & Crockett, P.C.

20090074820 - Aminoarylvinyl-s-triazine compounds and uses thereof: The invention relates to the use of at least one agent for screening out light radiation with a wavelength ranging from 370 to 500 nm as an agent for inhibiting the degradation of endogenous carotenoids present in the skin. The invention is useful for treating skin disorders caused by sunlight... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074819 - Polymeric nano-shells: The present invention provides a method for manufacturing polymeric nano-structures (nano-shells), wherein the nano-structures are hollow and respond to a temperature change by reversibly changing their volume, and the method comprises the steps of providing a polymer forming supramolecular structures when dispersed in a liquid environment, dispersing the polymer in... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20090074822 - Cosmetic compositions containing alpha glucosidase inhibitors and methods of use: A composition containing at least one alpha glucosidase inhibitor, and a method for ameliorating the adverse effects of aging and sun damage on keratinous surfaces such as skin by treating with a composition containing at least one alpha glucosidase inhibitor; as well as regimens and kits for treating skin.... Agent: Julie Blackburn

20090074821 - Oil absorbing cosmetic sheet: To provide an oil-absorbing cosmetic sheet having very excellent oil absorption property and remarkably soft touch and enabling oil removal with enjoyment before and during use by virtue of an imparted picture pattern. The oil-absorbing cosmetic sheet comprises a porous stretched film formed of a plastic material and is constructed... Agent: 3m Innovative Properties Company

20090074823 - Self tanning cosmetic:

20090074824 - Stable nanocapsule systems for the administration of active molecules: The invention is aimed at nanocapsule systems characterized in that they have high stability during long periods of time. These systems are useful for the controlled release of pharmacologically or cosmetically active ingredients of highly lipophilic nature. The system comprises nanocapsules with an average size less than 1 μm dispersed... Agent: Intellectual Property / Technology Law

20090074825 - Colorants based n-halamines compositions and method of making and using: The present invention includes methods, articles, compositions and colorant dyes and pigments that include biocidal N-halamine dye composition having two or more heterocyclic ring structures attached to one or more N-halamine groups, wherein one or more halogens associate with the one or more one or more N-halamine groups to affect... Agent: Chalker Flores, LLP

20090074826 - Extruded component with antimicrobial component: An extruded component formed from an extruded material having antimicrobial components is disclosed. The extruded material may be formed from polymers and formed into a generally elongated shape. The antibacterial components may extend from an outer surface of the extruded material radially outward. A color dye coating may be placed... Agent: Akerman Senterfitt

20090074827 - Coated pet food composition: A composition comprising a physically discrete pet food oral intake composition coated with a physically stable film, the film comprising a component which is a) capable of carrying a beneficial agent to a site in the pet wherein the benefit agent is effective in producing a beneficial effect or b)... Agent: Colgate-palmolive Company

20090074829 - Novel heparin alternative material and method for producing the same: The object is to provide a novel heparin alternative material, which is excellent in safety and in vivo degradability. Disclosed are: a novel heparin alternative material, which comprises an enzymatically synthesized α-1,4-glucan derivative and has functions substituting those of heparin, such as an anticoagulation activity and functions of a material... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090074828 - Poly(amino acid) targeting moieties: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090074830 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074833 - Bridged polycyclic compound based compositions for controlling bone resorption: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090074836 - Diffusion-hardened medical implant: The present invention relates to a new composition and medical implant made therefrom, the composition comprising a thick diffusion hardened zone, and preferably further comprising a ceramic layer. The present invention relates to orthopedic implants comprising the new composition, methods of making the new composition, and methods of making orthopedic... Agent: Smith & Nephew, Inc.

20090074835 - Human disc tissue: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of... Agent: Pearl Cohen Zedek Latzer, LLP

20090074831 - Local vascular delivery of mtor inhibitors in combination with peroxisome proliferators-activated receptor stimulators: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20090074832 - Medical scaffold, methods of fabrication and using thereof: Articles of manufacturing comprising electrospun elements having continuous or stepwise gradients of porosity, average pore size, weight per volume and/or of agents for promoting cell colonization, differentiation, extravasation and/or migration are provided. Also provided are methods of manufacturing and using same for guiding tissue regeneration.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090074834 - Method and system for modifying the wettability characteristics of a surface of a medical device by the application of gas cluster ion beam technology and medical devices made thereby: Irradiation of a surface of a material with a gas cluster ion beam modifies the wettability of the surface. The wettability may be increased or decreased dependent on the characteristics of the gas cluster ion beam. Improvements in wettability of a surface by the invention exceed those obtained by conventional... Agent: Burns & Levinson, LLP

20090074837 - Bioresorbable calcium-deficient hydroxyapatite hydrogel composite: The present invention provides a composite material comprising oxidized bacterial cellulose and calcium-deficient hydroxyapatite, and methods for preparing the composite material. The composite material is useful as a bone graft material. In another embodiment, the invention provides a method for tissue repair in a mammal. The method comprises inserting the... Agent: Ut-battelle, LLC Office Of Intellectual Property

20090074838 - Medical devices having bioerodable layers for the release of therapeutic agents: According to an aspect of the present invention, medical devices are provided which comprise: (a) a substrate, (b) an inner bioerodable polymeric layer over the substrate that comprises (i) 80 wt % or more of an amorphous biodegradable polymeric component and (ii) 20 wt % or less of a therapeutic... Agent: Mayer & Williams PC

20090074839 - Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications: Compositions having synergistic effective amounts of one or more antibacterial agents, a nitroimidazole, and/or a sulfonamide or a molecule or compound having folic acid antagonist effect and nitroimidazole substitution in addition, with or without an antifungal agent effective against a Candida species. The compositions are particularly useful in the treatment... Agent: Haugen Law Firm Pllp

20090074840 - Coated pet food composition: A composition comprising a physically discrete pet food oral intake composition coated with a physically stable film, the film comprising a component which is a) capable of carrying a beneficial agent to a site in the pet wherein the benefit agent is effective in producing a beneficial effect or b)... Agent: Colgate-palmolive Company

20090074842 - Medicament patch: A medicament patch comprises a release paper that oppositely lies on the surface of a patch carrier. The release paper is defined to, from right to left, a first teardown slice, a second teardown slice, and a third teardown slice. Each teardown-slice correspondingly matches with an adjacent edge of another... Agent: Chiayuan Chang

20090074841 - Medicament-based patch: A medicament-based patch comprises a release paper on the surface of a patch carrier, being defined to, from right to left, a first tear-down slice, a second tear-down slice, and a third tear-down slice. Each tear-down-slice correspondingly matches with an adjacent edge of another teardown slice through joints of concaves... Agent: Chiayuan Chang

20090074843 - Use of epi-hne 1-4: The invention relates to use of at least one of the compounds EPI-HNE 1, EPI-HNE 2, EPI-HNE 3 or EPI-HNE 4 for the manufacture of a medicament for treatment of chronic wounds or burns. The EPI-HNE 1-4 compounds are e.g. suitable for incorporation into a wound care device, such as... Agent: Jacobson Holman PLLC

20090074846 - Patch containing a medicament: A patch containing a medicament comprises a release paper oppositely lying on the surface of a patch carrier. The release paper is defined to, from right to left, a first teardown slice, a second teardown slice, and a third teardown slice. Each teardown slice correspondingly matches with an adjacent edge... Agent: Chiayuan Chang

20090074845 - Transdermal active principle delivery means: A transdermal active principle delivery means comprises a skin adherent or otherwise skin-tolerant substrate applicable to a skin area affected by DNA virus, which substrate includes a composition for treating DNA comprising a transdermally effective carrier medium including at least one active principle selected from the group consisting of diuretic... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090074844 - Trenadermal absorption preparation: The present invention relates to a blood concentration regulation type percutaneous absorption preparation, which comprises an ester form of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoic acid and a base for external preparations. The blood concentration regulation type percutaneous absorption preparation of the present invention can stably maintain blood concentration of the active form of the... Agent: Sughrue-265550

20090074849 - Cancer-suppressing agents: It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein... Agent: Birch Stewart Kolasch & Birch

20090074848 - Combination formulations of cytidine analogs and platinum agents: Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.... Agent: Morrison & Foerster LLP

20090074851 - Cpg-packaged liposomes: Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090074852 - Lipoplex formulations for specific delivery to vascular endothelium: The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090074847 - Transport system in biological systems: The invention relates to a transport system (1) for active substances containing hybrid particles (2) comprising at least one layer of lipid molecules (3) and at least one ligand, the ligand being a peptide (5).... Agent: Collard & Roe, P.C.

20090074850 - Use of a topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention: The present invention is related to the use of topical formulations that contain epidermal growth factor encapsulated in or associated to deformable or conventional liposomes to be applied on the surface of and around chronic ischemic skin lesions. The formulations of the present invention, in contrast with the previous art,... Agent: Hoffmann & Baron, LLP

20090074853 - Vaccines with enhanced immune response and methods for their preparation: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090074854 - Combined-step process for pharmaceutical compositions: The invention relates to a process for the solid oral pharmaceutical formulation of a pharmaceutically active ingredient such as levetiracetam, comprising a wet granulation of the pharmaceutically active ingredient and simultaneous fluid bed drying such that, as the pharmaceutical blend granulates it is simultaneously dried thus preventing it from becoming... Agent: Amin Hallihan, LLC

20090074855 - Enteric coastings for orally ingestible compositions: A suspendible enteric coating composition for encasing orally ingestible articles wherein the enteric coating composition comprises a pH-dependent polymer selected from a group containing alginates and alginic acids, a pH-independent water insoluble polymer selected from the group comprising ethylcellulose and ethylcellulose-containing compositions, and a plasticizer selected from the group containing... Agent: Fasken Martineau Dumoulin, LLP

20090074856 - Crystalline pyrimidine nucleoside derivative suspensions in capsules: The present invention relates to a pharmaceutical formulation which comprises (i) a capsule, and (ii) a core comprising crystalline 2′-cyano-2′-deoxy-N4-palmitoyl-1-β-D-arabinofuranosylcytosine and a liquid carrier.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090074857 - Glycerophospholipids for the improvement of cognitive functions: e

20090074859 - Solid carriers for improved delivery of active ingredients in pharmaceutical compositions: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat... Agent: Thorpe North & Western, LLP.

20090074858 - Sustained-release formulation: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient.... Agent: Leydig Voit & Mayer, Ltd

20090074860 - Nutritional beverage with skin improvement aids: This invention provides a nutritional beverage solution assistive to the visual appearance of a consumer's skin. In optional preferred embodiments, the solution includes primary antioxidant Vitamins C & E, secondary antioxidant of at least one of a Grape Seed Extract, a Papaya Extract, a Guava Extract, an Acai Extract, a... Agent: Lackenbach Siegel, LLP

20090074863 - Dosage forms containing a ppi, nsaid and a buffer: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.... Agent: Dykema Gossett PLLC

20090074862 - Low-dose doxepin formulations and methods of making and using the same: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.... Agent: Knobbe Martens Olson & Bear LLP

20090074861 - Stable tablet containing droxidopa: A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived... Agent: Leydig Voit & Mayer, Ltd

20090074864 - Novel antimicrobial peptides with heparin binding activity: The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the... Agent: Merchant & Gould PC

20090074865 - Oral formulations of glycyl-2-methylprolyl-glutamate: Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an... Agent: Borson Law Group, PC

20090074866 - Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum: In one aspect, the present invention features a method of making a coated tablet, by dipping a core including an active agent into a coating liquid and drying the dipped core to form a outer-coating on said core, wherein the coating liquid includes (i) at least one copolymer of polyvinyl... Agent: Philip S. Johnson Johnson & Johnson

20090074867 - Orally dispersible pharmaceutical composition and process for the preparation thereof: A process for preparing an orally dispersible solid pharmaceutical form comprises the following steps: a) coating the active ingredient with at least one hydrophilic carboxylate polymer, b) granulating the coated active ingredient obtained in step (a) with at least one lipid compound having a melting point lower than that of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090074869 - Pharmaceutical formulations: Disclosed are pharmaceutically acceptable PDE V inhibitor Formulations that are especially useful for treating male erectile and female sexual dysfunction and other physiological disorders.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090074868 - Photoinitiated tissue filler: Visible light-activated polymer cosmetic filler preparations useful in a variety of applications are provided. In some embodiments, the photo-activated polymer composition comprises a conventional polymeric material, such as HA, together with a modified, cross-linkable polymer, such as PEG or PEODA, to permit the formation of crosslinks within the polymer matrix... Agent: Edwards Angell Palmer & Dodge LLP

20090074872 - Active agent formulations, methods of making, and methods of use: Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days.... Agent: Cantor Colburn, LLP

20090074870 - Alteration of cell membrane for new functions: Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed... Agent: Foley And Lardner LLP Suite 500

20090074871 - Composition for filling bone defects: The invention is directed toward an improved formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles ranging from about 100 to 850 microns. The bone particles are... Agent: Jones Day

20090074873 - Nanoparticulate beclomethasone dipropionate compositions: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090074874 - Process for producing polymer micelles encapsulating low molecular weight drugs: The present invention provides a method of encapsulating a low molecular weight drug in a polymer micelle, the method comprising the steps of: (a) dissolving or dispersing the drug having an electric charge in an aqueous medium; (b) preparing an aqueous medium containing a polymer micelle comprising a block copolymer... Agent: Christie, Parker & Hale, LLP

20090074875 - Nanoparticulate compositions having lysozyme as a surface stabilizer: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090074876 - Peptide composition and a method of promoting cartilage formation: The present invention is a peptide compound which stimulates the formation of hard tissues such as bone and cartilage. The invention is also related to a method to treat a defect in hard tissues such as bone and cartilage using the peptide. The method of the present invention may be... Agent: Bozicevic, Field & Francis LLP

20090074877 - Water containing active hydrogen and process for producing the same: Provided are novel water containing active hydrogen wherein the content of active hydrogen is high and a process wherein such active hydrogen-containing water is produced simply at high efficiency from an inexpensive material without needing complex apparatus or special treating agents. The water containing active hydrogen of the present invention... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090074878 - Non-toxic water soluble inorganice antimicrobal polymer and related methods: The present invention provides a non-toxic water soluble, inorganic anti-microbial polymer for inactivating microorganisms. The polymer is obtained by forming an aqueous solution comprising alkali metal cations, phosphate anions, carbonate anions, and hydrogen ions. The polymer has antimicrobial activity while in suspension and forms a hard, contiguous, encapsulating antimicrobial transparent... Agent: Trask Britt

20090074881 - Antimicrobial cidality formulations with residual efficacy, uses thereof, and the preparation thereof: The present invention is a quick-kill formulation that is able to kill organisms such as bacteria, viruses, fungi, mold, spore-forming bacteria and combinations thereof. In addition, the formulation contains a residual kill component that is effective for at least one day. The unique formulation is effective without being corrosive. This... Agent: Gearhart Law, LLC

20090074880 - Method for oxygen treatment of intact skin: Oxygen therapy for healthy or inflamed but intact skin involves placing an oxygen-generating dressing onto the skin to be treated, the oxygen-generating bandage being a one-time use dressing capable of generating oxygen for only a short period of time, not to exceed about 4 hours.... Agent: Brooks Kushman P.C.

20090074879 - Wound-healing composition: Disclosed are topical formulations containing hyaluronic acid, hydrogen peroxide or other antiseptic agents and optionally adenosine, aminoacids and plant extracts.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090074882 - Insulin compositions and method of making a composition: The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090074883 - Multivitamin and mineral compositions for individuals having renal disease: The present invention relates to oral compositions which are useful for nutrient supplementation. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of patients in various stages of chronic kidney disease and supplementing levels of physiological anti-oxidants, vitamins, and minerals in... Agent: Casimir Jones, S.c.

20090074884 - Family of pfkfb3 inhibitors with anti-neoplastic activities: A methods and compounds for inhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) are described. Also described are methods of inhibiting cell proliferation, treating cancer, and screening compounds to determine their ability to inhibit PFKFB3.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090074885 - Reversible hydrophobic modification of drugs for improved delivery to cells: Described are drug formulations that increase regional delivery of the drugs to cells. Methods for reversibly increasing the hydrophobicity of a drug through hydrolytically labile attachment of a hydrophobic moiety and methods for delivering the modified drug to cells are described. Hydrophobic modification increases drug delivery, while lability minimizes entry... Agent: Roche Madison Inc.

20090074886 - Gsk-3 inhibitors: This invention relates to methods of treating or preventing bone loss by administering to a human or animal subject pyrimidine and pyridine derivatives that inhibit the activity of glycogen synthase kinase 3 (GSK3), to pharmaceutical compositions containing the compounds, and to the use of the compounds and compositions alone or... Agent: Novartis Vaccines And Diagnostics Inc.

20090074887 - Fungicidal active compound combinations: i

20090074888 - Stable cleanser compositions containing sulfur: The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders.... Agent: Reed Smith LLP

20090074889 - Compositions and methods for treatment and prevention of osteoarthritis: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. In one aspect, the invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090074890 - Substituted triazoles as sodium channel blockers: Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or... Agent: Merck And Co., Inc

20090074891 - Combretum laurifolium mart. extract and methods of extracting and using such extract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract... Agent: Cox Smith Matthews Incorporated

20090074892 - Compositions and methods for alleviating skin disorders: The disclosure relates to the discovery that fractionated coconut oil is effective for alleviating existing skin disorders when applied topically to the skin of a person afflicted with such a disorder. The disclosure further relates to the discovery that fractionated coconut oil can be used to prevent or inhibit onset... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090074893 - Antiviral peptides: The invention provides a method for the prevention or treatment of virus infections comprising administering, to a human or animal individual susceptible to or suffering from a virus infection, an effective amount of one or more casein phosphopeptides (CPP). Also provided is a composition containing such casein peptides and further... Agent: Young & Thompson

20090074894 - Identification of bitter receptors for hydrolyzed soy protein: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in hydrolyzed soy protein derived materials. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation... Agent: Hunton & Williams LLP Intellectual Property Department

20090074895 - Composition and uses thereof: The present invention relates to a composition used to treat hyperglycaemia and associated conditions. In particular, the present invention relates to a composition comprising an extract from at least one plant from the genus Stevia and at least one bile salt, salt thereof or derivative thereof admixed in a form... Agent: Frommer Lawrence & Haug

20090074896 - Extracts of polygonum multiflorum thunb, and preparation process and uses of the same: Disclosed herein are processes for preparing extract products from the root of Polygonum multiflorum Thunb. and the extract products thus obtained, which are biologically active in promoting the proliferation, growth and/or differentiation of hematocytes and bone marrow cells in vitro and in vivo.... Agent: Panitch Schwarze Belisario & Nadel LLP

20090074897 - Agent for elevating adiponectin concentration: To provide a highly safe medicament or food or beverage which exhibits the effect of elevating blood adiponectin level, and which allows intake thereof over a long period of time. The invention provides an adiponectin level elevating agent including guava leaf extract as an active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090068094 - Inhibitors of endo-exonuclease activity for treating cancer: The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in... Agent: Millen, White, Zelano & Branigan, P.C.

20090068098 - Antibodies and related molecules that bind to 58p1d12 proteins: Antibodies and molecules derived therefrom that bind to 58P1D12 protein and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12... Agent: Agensys C/o Morrison & Foerster LLP

20090068099 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090068100 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090068095 - Carbonic anhydrase ix (g250) anitbodies and methods of use thereof: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090068097 - Method for non-invasive detection and treatment of cerebral aneurysms: Described herein is a method for non-invasive detection and treatment of intra-cranial aneurysms. Antibodies are provided to specifically react/bind with antigens of the cerebral aneurism wall. The antibodies may be bound to a label and/or to a therapeutic agent for diagnosis and/or for treatment purposes thereof. Intra-cranial aneurysms are thus... Agent: Fulbright & Jaworski, LLP

20090068096 - Sequence of stro-1 antibody variable region: The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein.... Agent: Myers Bigel Sibley & Sajovec

20090068103 - Aptamers labeled with 68ga: This invention relates to novel nucleotide-based compounds, methods of making radiolabeled compounds and use of such compounds for diagnostic imaging. Provided are compounds according to Formula (I) A-B-L-C, wherein A stands for an aptamer, B is absent or stands for a bridging structure, L is a linker, and C is... Agent: Millen, White, Zelano & Branigan, P.C.

20090068104 - Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate has a predetermined ratio of drug molecules to protein molecules that preferentially bind to such cells and a method for making such a conjugate. The method of making the conjugate comprises adding drug molecules to linker molecules in... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090068102 - Treating stroke: Methods of treating stroke with blocking agents of TWEAK or TWEAK receptor are presented.... Agent: Biogen Idec / Finnegan Henderson, LLP

20090068105 - Isatin analogues and uses therefor: Novel isatin analogues, including isatin analogues comprising Michael Acceptors (IMAs) are disclosed. Further disclosed are methods of synthesis of the isatin analogues, and uses of the analogues, including inhibition of caspase-3 and caspase-7, and in vivo imaging of apoptosis by Positron emission tomography (PET) or Single Photon Emission Computed Tomography... Agent: Sonnenschein Nath & Rosenthal LLP

20090068109 - Anti-mcp-1 antibodies, compositions, methods and uses: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20090068108 - Biospecific contrast agents: Methods and apparatuses for detecting a condition of a sample (including cervical cancers and pre-cancers) through reflectance and/or fluorescence imaging. A sample is obtained. One or more metallic nanoparticles and/or one or more quantum dots are obtained. The one or more metallic nanoparticles and/or one or more quantum dots are... Agent: Fulbright & Jaworski L.L.P.

20090068106 - Conjugation product: A peptide which selectively inhibits αvβ3 integrin which comprises the deamidation product of a peptide comprising the NGR motif.... Agent: Foley And Lardner LLP Suite 500

20090068107 - Enzyme regulating ether lipid signaling pathways: A multidimensional profiling strategy that combines activity-based proteomics and metabolomics was used to determine that an active protein, which is a previously uncharacterized enzyme highly elevated in aggressive cancer cells, serves as a central node in an ether lipid signaling network that bridges platelet-activating factor and the lysophospholipids. Biochemical studies... Agent: Dla Piper LLP (us)

20090068110 - Antibodies to insulin-like growth factor receptor: The invention provides various antibodies that bind to insulin-like growth factor-I receptor (IGF-1R), methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, cancer or aging. The antibodies include murine, chimeric, and humanized antibodies.... Agent: Genentech, Inc.

20090068111 - Methods of identifying lead compounds that modulate toxicity of neurotoxic polypeptides: Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's... Agent: Fish & Richardson P.C.

20090068112 - Magnetic nanoparticles for imaging: A medical imaging system that enables the discovery of malignant tissue utilizing contrast agents and heating agents made of magnetic nanoparticles that are delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites is disclosed. The thermal contrast agents may be temperature self-controlled magnetic... Agent: Akerman Senterfitt

20090068114 - Noninvasive thermometry monitoring system: A noninvasive thermometry monitoring system for determining a temperature of tissue to which hyperthermia treatment is administered is disclosed. The monitoring system may incorporate magnetic nanoparticles having known moments such that once exposed to an alternating magnetic field, the magnetic nanoparticles increase in temperature. Imaging systems can disclose the magnetic... Agent: Akerman Senterfitt

20090068115 - Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor: Amine functionalized magnetic nanoparticle compositions and processes for synthesizing the same are described. The process consists of obtaining a carboxylated polymer in substantially pure form, which is used to prepare a substantially size homogeneous, polymer coated carboxyl, functionalized magnetic nanoparticle. The carboxyl groups are converted to reactive primary amino groups... Agent: Goodwin Procter LLP Patent Administrator

20090068113 - Amphiphilic squaraine dyes, process for preparation thereof and use thereof: The present invention relates to amphiphilic squaraine dyes of the general formula (1) as shown below Formula (1) wherein, R1=—(CH2—CH2—O)n—CH3, n=4-8, or —(CH2)n—CO2X, n=3-6, X=H, succinamide and R2=—CH3 or —(CH2—CH2—O)n—CH3, n=4-8 and pharmaceutically acceptable derivatives thereof, for use as near infrared fluorescence probes in photodynamic diagnostic and biological, biochemical and... Agent: Fulbright & Jaworski L.L.P.

20090068116 - Chemical system with self-timing indicator: A luminescent composition, with a luminescent marker and a ionizing agent exhibiting luminescence for an indicatory period once intermixed, and with luminance intensity remaining at a threshold intensity during indicatory period. Luminescence also can be exhibited responsive to responsive to excitatory light applied to the composition. The luminescent marker includes... Agent: Wang, Hartmann & Gibbs

20090068118 - Device for delivery of a foamable composition: A device for delivery of a foamable composition to a body cavity includes a pressurized composition reservoir; a hollow body having a longitudinally extending wall and having at least one aperture provided through a wall of said body, the proximal end in fluid communication with the reservoir for receiving a... Agent: Wilmerhale/boston

20090068117 - Stay-on selenium foam: Provided, among other things, is a delivery module for a non-greasy, non-irritating selenium sulfide composition comprising: (A) an aerosol delivery device; (B) within the aerosol delivery device, the selenium sulfide composition comprising an effective amount of selenium sulfide that is 1% or more by weight of the composition, and a... Agent: MoserIPLaw Group

20090068119 - Sprayable depilatory composition and a method of use: A sprayable depilatory composition including a depilatory agent; a surfactant present in the range 0.1% to 5.0% by weight of the composition, wherein the composition has an initial viscosity substantially less than about 7.00 Pas.... Agent: Trask Britt

20090068120 - Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same: s

20090068121 - Lantibiotics and uses thereof: The present invention provides isolated lantibiotics that inhibit Gram negative and Gram positive microbes. The lantibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have... Agent: Mueting, Raasch & Gebhardt, P.A.

20090068122 - Dentifrice compositions for treating xerostomia: This invention encompasses an oral composition for treating or preventing dry mouth with following benefits: antibacterial/anti-fungal efficacy, low irritancy, and moisture retention. The compositions can be a toothpaste, a mouth rinse or a spray and include one or more non-ionic surfactants, as foaming agents, one or more broad spectrum anti-microbial... Agent: Colgate-palmolive Company

20090068123 - Fluorine ion-releasable composition for dental purposes: Since the fluoride ion releasing dental composition of this invention provides dentine with a high cariostatic property over a long period of time by gradually releasing fluoride ions, it is suitably used as a dental adhesive material, a dental filling material, a dental resin used for forming an abutment, a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090068124 - Novel heterocyclic substituted condensation polymers: The invention relates to novel optionally quaternized or protonated condensation polymers having at least one heterocyclic end-group connected to the polymer backbone through a unit derived from an alkylamide, the connection comprising an optionally substituted ethylene group and to the use thereof in body care products and household products.... Agent: Nixon & Vanderhye, PC

20090068125 - Treatment for mucositis: This invention relates to a medicament for protecting human mucosal cells from chemotherapy or radiotherapy induced cell death using formulations comprising adenosine or adenosine analogues as a reversible inhibitor of epithelial cell proliferation. The invention also relates to formulations containing adenosine for the prevention of or reduction in mucositis symptoms.... Agent: Seed Intellectual Property Law Group PLLC

20090068129 - Aminophenylbenzothiazole compounds: i

20090068126 - Composition for surface photoprotection: The molecules capable of absorbing ultraviolet radiation from the cashew nut shell liquid changes are the object of the present invention; it is also described the compositions responsible for protecting the surfaces and chemical processes for the referred molecules production.... Agent: Carter, Deluca, Farrell & Schmidt

20090068127 - Novel polysiloxane sunscreens: The present invention relates to novel sunscreens on the basis of polysiloxanes, to their preparation and to their use, especially in formulations for the protection against harmful effects of sunlight.... Agent: Nixon & Vanderhye, PC

20090068128 - Scar and rosacea and other skin care treatment composition and method: The present invention relates generally to composition and methods for topical application to skin. More particularly, it relates to treatment of scars and rosacea, and other aspects of skin care. A composition is disclosed having a skin toner for cleansing a skin surface, removing dead skin cells, restoring alkali balance,... Agent: Schmeiser, Olsen & Watts

20090068130 - Sunless tanning composition with photostablized sunscreen: In one aspect, a cosmetic composition includes a sunless tanning agent and a sunscreen agent. A photostabilizer is added to stabilize the sunscreen agent from the destabilizing effect of the sunless tanning agent. In this manner, UV protection is provided to the user when the cosmetic composition is applied to... Agent: Michaud-duffy Group LLP

20090068131 - Water-based nail-polish composition: The water-based nail-polish composition includes a mixture of at least one water-based suspension (A) of hard nanoparticles of an acrylic polymer at a glass transition temperature that is greater than or equal to 55° C., in combination with at least one coalescent and/or plasticizing solvent of the polymer; and at... Agent: Young & Thompson

20090068132 - Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same: The present invention relates to cosmetic compositions containing resveratrol ferulate in a topically acceptable carrier. Such compositions are particularly effective for skin lightening and anti-aging applications and have excellent color stability and extended shelf life.... Agent: The Estee Lauder Cos, Inc

20090068133 - Composition containing a liquid fatty phase gelled with a semi-crystalline copolymer: The invention relates to a semi-crystalline copolymer of organic structure with a melting point of greater than or equal to 30° C. obtained from at least two monomers A and B, A being a lipophilic monomer bearing crystallizable side chain(s) and B being an amorphous lipophilic monomer that is copolymerizable... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090068134 - Hair cosmetic: wherein R1CO represents fatty acid residues among which C20 or more fatty acid residues account for 60 percent by weight or more, C20 fatty acid residues account for 3 percent by weight or more, and C22 fatty acid residues account for 50 to 95 percent by weight; (b) an organic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090068135 - Durable fiber treatment composition: A fiber treatment composition is presented comprising organomodified silicones having defined physico-chemical properties and a additive which allows the organomodified silicone to be retained on the hair over longer periods of time than traditionally has been the case. The present composition finds particular application on hair that has been damaged... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090068136 - Hair care compositions: The invention relates to hair care compositions comprising an effective amount of a condensation polymer having at least one, optionally quarternized or protonated, dialkylamide end-group connected through the polymer backbone to a unit derived from an alkylamide, the connection comprising at least one ester linkage.... Agent: Nixon & Vanderhye, PC

20090068137 - Organoleptic compounds and their use in perfume compositions: e

20090068138 - Polyglycerol anti-microbial agents and compositions: Polyglycerol anti-microbial agents and compositions are provided. The agents are effective against a variety of pathogens including fungi, Gram positive bacteria and Gram negative bacteria yet are expected to have low human toxicity due in part to their polymeric nature. Applications for the polyglycerol anti-microbial agents and compositions include those... Agent: Joann Villamizar Ciba Corporation/patent Department

20090068139 - Loop peptide and tgf alpha for stimulating stem cell proliferation and migration: There is disclosed a novel genus of small peptides, smaller than human TGFα, identified as having TGFα biological activity and therefore being useful as pharmacologic agents. It is further disclosed that both TGFα and the genus of small peptides disclosed herein have therapeutic activity to stimulate hematopoiesis, e.g., in patients... Agent: Seed Intellectual Property Law Group PLLC

20090068141 - Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer: The invention provides a simple, cost-effective method of preparing a composition comprising natural killer (NK) cells useful for administering to a human. The method comprises (i) depleting CD3+ cells from a population of PBMCs comprising NK cells, and (ii) co-culturing cells from (i) with irradiated PBMCs that are autologous to... Agent: Leydig, Voit & Mayer, Ltd.

20090068140 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090068142 - Compositions and methods for treating coronavirus infection and sars: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that... Agent: Arent Fox LLP

20090068143 - Orally effective cannabinoid analogs: The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB2, especially (+)-α-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for prevention, alleviation or treatment of autoimmune neurodegenerative disorders, in particular multiple sclerosis and associated symptoms. Methods of the invention are useful when the active... Agent: Fennemore Craig

20090068146 - Diaryl ureas and combinations: e

20090068145 - Methods and compositions relating to islet cell neogenesis: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.... Agent: Pepper Hamilton LLP

20090068144 - Tetrahydro-isoquinolin-1-ones for the treatment of cancer: The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord... Agent: Dann, Dorfman, Herrell & Skillman

20090068148 - Peptides of cav2.2 that inhibit pain: The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat... Agent: Fulbright & Jaworski L.L.P.

20090068147 - Raav vector-based pro-opiomelanocortin compositions and methods of use: Disclosed are methods for the use of pro-opiomelanocortin-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions, virions, and pluralities of virus particles that comprise a nucleic acid segment that expresses one or more mammalian pro-opiomelanocortin polypeptides... Agent: Haynes And Boone, LLPIPSection

20090068157 - Derivation of unlimited quantities of neutrophils on monocyte/dendritic cells: A method to generate unlimited numbers of macrophage/dendritic cells or neutrophils from mice, using conditional Hox oncoproteins is disclosed. The invention further includes the establishment of a system to investigate immune responses to microorganisms or diseases involving chronic inflammation.... Agent: Dla Piper LLP (us)

20090068159 - Insecticidal compositions and methods for making insect-resistant transgenic plants: The present invention provides isolated polynucleotide sequences encoding ET37, TIC810 and TIC812 proteins from Bacillus thuringiensis, and nucleotide sequences for use in expressing TIC809, ET37, TIC810 and TIC812, and fusions of various insecticidally effective combinations of these proteins such as TIC 127, in plants. Methods of making and using the... Agent: Monsanto Company

20090068158 - Thymidylate kinase mutants and uses thereof: The invention relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of... Agent: Fox Rothschild LLP

20090068149 - Use of a fermented milk containing l. casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction: The present invention relates to the field of probiotics. More particularly, the invention pertains to the use of a particular strain, Lactobacillus casei CNCM I-1518, which is present in Actimel®, for alleviating the symptoms of a delayed-type hypersensitivity reaction.... Agent: Morgan Lewis & Bockius LLP

20090068150 - Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same: Disclosed is a lactic acid bacteria culture of mung bean obtained by culturing lactic acid bacteria in a culture medium containing mung bean extract. The culture contains the mung bean extract and GABA (ϝ˜ Aminobutyric acid), so that it exhibits effects of promoting collagen synthesis and alleviating inflammation. Accordingly, the... Agent: Merchant & Gould PC

20090068161 - Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin: The cosmetic use of at least an effective amount of hesperidin or of one of its derivatives in combination with at least an effective amount of at least one microorganism, in particular probiotic microorganism, or one of its fractions as agent for preventing a reduction in and/or for reinforcing the... Agent: Oliff & Berridge, PLC

20090068160 - Use of a lysate of bifidobacterium species for treating sensitive skin: Cosmetic use of an effective amount of at least one lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof, for preventing and/or treating a skin disorder in the case of sensitive skin.... Agent: Oliff & Berridge, PLC

20090068151 - Methods and reagents for the enhancement of virus transduction in the bladder epithelium: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a... Agent: Ropes & Gray LLP

20090068153 - Cell composition for tissue regeneration: A method of extracting human progenitor cells from perivascular tissue of human umbilical cord. The extracted cells are then co-cultured with hematopoetic stem cells and are useful to grow and repair human tissues including bone. Also included are related methods and compositions related thereto.... Agent: Ladas & Parry LLP

20090068154 - Cell composition for transplant: The present invention provides a cell composition for transplant comprising fibroblasts originating in buccal fat pad.... Agent: Birch Stewart Kolasch & Birch

20090068152 - Gene transfer for regulating smooth muscle tone: The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of... Agent: Amster, Rothstein & Ebenstein LLP

20090068155 - Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system: Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity,... Agent: Altera Law Group, LLC

20090068156 - Treatment of muscular dystrophy with cord blood cells: The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion.... Agent: Clark & Elbing LLP

20090068162 - Stationary phase antibody arrays for trace protein analysis: The present invention relates to the identification of trace proteins and biomarkers, e.g., TH-1/TH-2, cytokines, MMPs and angiogenic modulators in tear fluids. The present invention provides an antibody-based stationary phase array assay for simultaneously identifying, detecting and characterizing the distribution of a wide range of bioactive trace proteins in a... Agent: Scully Scott Murphy & Presser, PC

20090068163 - Transgenic expression cartridges for expressing nucleic acids in the flower tissue of plants: The invention relates to methods for the targeted transgenic expression of nucleic acid sequences in tissues of plants, and to transgenic expression cassettes and expression vectors comprising promoters with expression specificity for floral tissues. The invention further relates to organisms (preferably plants) transformed with these transgenic expression cassettes or expression... Agent: Connolly Bove Lodge & Hutz, LLP

20090068166 - Method and composition for protection against radiation: Methods are described for using an arginine depleting agent such as arginase and derivatives thereof, which reduce physiological arginine levels, as radioprotectants to protect normal mammalian cells from DNA damage caused by ionizing radiation. Treatment can result in the protection of normal tissues in cancer patients undergoing radiotherapy and in... Agent: EagleIPLimited

20090068164 - Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences: The present invention provides a nucleotide sequence detection system in which a reporter enzyme is split into two halves each half of which is associated with at least one zinc finger domain. Upon DNA binding to the specific sequence defined by the zinc finger domains associated with the respective halves,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090068165 - Uniformly conjugated serine hydrolases: An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20090068167 - Compositions for promoting wound healing and treating psoriasis: The present invention relates to compositions and methods for promoting healing of cutaneous, mucosal and/or mucocutaneous lesions associated with the presence of a mycoplasma and one or more non-mycoplasma microorganisms. The compositions and methods of the invention also relate to the reduction of joint pain, column pain, and/or skeletal muscle... Agent: Baker Botts L.L.P.

20090068168 - Substituted amino alcohols: Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090068101 - A1 adenosine receptor antagonists: This invention relates to compounds of formula (I): wherein R1 is a branched or straight chain C1-C6 alkyl; R2 is of the formula (II), wherein n is an integer ranging from 1 to 8; R5 is H or (CH2)pCH3, and R6 is H or (CH2)mOH, wherein p is an integer... Agent: Alston & Bird LLP

20090068169 - 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use: The present invention describes new compounds which are useful for binding to the tail or Fc portion of immunoglobulins and so have utility in those applications which require the non-covalent binding interaction of a molecule with the Fc portion of immunoglobulins. Such applications include the detection and purification of immunoglobulins... Agent: Nixon & Vanderhye, PC

20090068170 - Droplet-based selection: The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is... Agent: Wolf Greenfield & Sacks, P.C.

20090068171 - Protein markers for the detection of thyroid cancer metastasis: This invention relates, e.g., to a method for detecting the presence of lymph node metastases in a subject having papillary thyroid carcinoma (PTC), comprising measuring in a sample from the subject the amount of expression (e.g., the amount of protein, or the amount of mRNA encoding the protein) of one... Agent: Venable LLP

20090068172 - Compositions and methods comprising binding proteins for adalimumab: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including... Agent: Abbott Bioresearch

20090068181 - Bispecific antibodies: The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue.... Agent: Townsend And Townsend And Crew, LLP

20090068178 - Compositions and methods for the treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20090068180 - Compositions and methods for treating immunological and inflammatory diseases and disorders: Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent.... Agent: Lexicon Pharmaceuticals, Inc.

20090068182 - Cytotoxicity mediation of cells evidencing surface expression of cd9: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20090068176 - Human neutralizing antibodies aganst hemolytic uremic syndrome: Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg... Agent: Pabst Patent Group LLP

20090068183 - Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same: The present invention is directed to compounds, agents, pharmaceutically active agents, medicaments, therapeutics, actives, drugs and the like which specifically target a portion of the HAS molecule which is accessible to the extracellular environment in a first form of a cell but which is not accessible to the extracellular environment... Agent: Morrison & Foerster LLP

20090068179 - Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors: Methods for inhibiting carcinogenesis and/or metastasis in an individual comprise administering to the individual an effective amount of endogenous c-met ligand or fragment thereof such as endogenous anti c-met immunoglobulin, native and/or recombinant; endogenous biological active Hepatocyte Growth Factor (HGF), native and/or recombinant, and/or a combination thereof.... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20090068173 - Novel cc-chemokine antagonists: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090068175 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Xencor

20090068177 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20090068174 - Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining: A method of treating an inflammatory condition involving TNF-α in a mammal by administering to a patient a composition with an effective amount of an isolated alkaline protease in an amount effective to inactive TNF-α. The invention also involves compositions, including pharmaceutical compositions containing an isolated alkaline protease in an... Agent: Hunton & Williams LLP Intellectual Property Department

20090068184 - Engineered antibody-stress protein fusions: Provided are fusion polypeptides comprising an engineered antibody and a stress protein that bind to antigens with high affinity, are highly immunogenic, exhibit MHC class I priming and are able to be produced in non-mammalian cells, such as E. coli.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090068185 - Asthma associated factors as targets for treating atopic allergies including asthma and related disorders: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its... Agent: Morgan Lewis & Bockius LLP

20090068188 - C-c chemokine receptor 3 proteins: The present invention relates to methods of inhibiting a mammalian C-C chemokine receptor 3 protein (CCR3). The invention further relates to methods of treating an inflammatory disease or condition. Administration of a compound which inhibits or promotes CCR3 function to an individual in need of therapy provides a new approach... Agent: Mcdermott Will & Emery LLP

20090068186 - Map3ks as modifiers of the p53 pathway and methods of use: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090068187 - Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have... Agent: Millennium Pharmaceuticals, Inc.

20090068190 - Anti-proliferative combinations: Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing... Agent: Kv Pharmaceutical Company

20090068189 - Monoclonal antibody to human tgf-beta induced gene-h3 and use thereof: The present invention relates to a monoclonal antibody to human βig-h3 and the use thereof. More particularly, it relates to a monoclonal antibody to the human βig-h3 protein, wherein the epitope of the monoclonal antibody is the H1 region of the fourth fas-1 domain of the human βig-h3 protein. The... Agent: Buchanan, Ingersoll & Rooney PC

20090068191 - Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype: The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090068192 - Fully human antibodies against human 4-1bb: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective... Agent: Louis J. Wille Bristol-myers Squibb Company

20090068193 - Treatment and prophylaxis with 4-1bb-binding agents: Materials and Methods for using 4-1BB agonists to treat or prevent autoimmune disorders, lymphoproliferative diseases, and allergies are provided.... Agent: Fish & Richardson P.C.

20090068194 - Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary... Agent: Choate, Hall & Stewart LLP

20090068195 - Methods and compositions for treating and monitoring treatment of il-13-associated disorders: Methods and compositions for reducing or inhibiting, or preventing or delaying the onset of, one or more symptoms associated with an early and/or a late phase of an IL-13-associated disorder or condition using IL-13 binding agents are disclosed. Methods for evaluating the kinetics and/or efficacy of an IL-13 binding agent... Agent: Lowrie, Lando & Anastasi, LLP W2023

20090068196 - Pharmaceutical formulation of an antibody against il13ralpha1: Pharmaceutical formulations of an antibody against IL13Rα1 and processes for making the same.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090068197 - Mycobacterial disease detection, treatment, and drug discovery: Methods for detecting and treating Mycobacterium-related diseases including reducing Mycobacterial virulence, reducing RV3133c dimerization, and treating a subject with a Mycobacterial infection using identified compounds are disclosed. Examples of compounds useful in the treatment of Mycobacterium-related diseases include N-(4-[(acetylamino)sulfonyl]phenyl)-3-phenylpropanamide; 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(2-imino-3-methyl-2,3-dihydro-1H-benzimidazol-1yl)ethanone hydrochloride; and 1-(1,3-benzoxazol-2-yl)-3-({4-[(2-hydroxyethyl)sulfonyl]phenyl}amino)acrylaldehyde. Further disclosed are methods for identifying agents... Agent: Fish & Richardson P.C.

20090068198 - Antibody and uses thereof: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative... Agent: Ip Group Of Dla Piper US LLP

20090068200 - Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer, and therapeutic use of prongf: s

20090068199 - Methods for treating and detecting beta-cell disease: The role of synaptic adhesion molecules in human cell development and function is largely unknown. This invention provides methods to study β-cell function in native tissue through the use of novel adhesion and migrations assays. Through the use of these assays, the inventors have been able to for the first... Agent: Spencer Fane Britt & Browne LLP

20090068201 - Methods of treatment using antibodies to neutrokine-alpha: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV... Agent: Leydig, Voit & Mayer Ltd.

20090068202 - Humanized anti-cd79b antibodies and immunoconjugates and methods of use: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP

20090068205 - Erbb4 antagonists: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090068203 - Methods for treating cardiovascular disease using a soluble ctla4 molecule: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090068204 - Morinda citrifolia based formulations for regulating t cell immunomodulation in neonatal stock animals: Both liquid and dry form Morinda citrifolia enhanced animal food products are provided for increasing CD8+ T cell activation in new born animals. Both contain M. citrifolia fruit puree and other M. citrifolia plant products.... Agent: Kirton And Mcconkie

20090068206 - Delivery of pharmaceutical agents via the human insulin receptor: A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human organs and tissue that express the HIR. The humanized murine antibody is especially well suited for delivering neuropharmaceutical... Agent: Quine Intellectual Property Law Group, P.C.

20090068207 - Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease: Methods and compositions employing beta2-glycoprotein-1 (β2GPI)-derived peptides and combinations thereof effective in inducing mucosal tolerance to atheroma related antigens and effective in inhibiting inflammatory processes contributing to atheromatous vascular disease and sequalae are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090068209 - Cytotoxic lymphocyte: The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.... Agent: Birch Stewart Kolasch & Birch

20090068210 - Immunotherapy for hematological malignancies: Methods and compositions for treating, preventing and/or managing various hematological malignancies are disclosed. Specific methods and compositions relate to use of tumor cells engineered to express antigen presenting molecules which present antigens recognized by iNKT cells and eliciting antitumor immune response from iNKT cells using such tumor cells, optionally in... Agent: Jones Day

20090068208 - Long term disease modification using immunostimulatory oligonucleotides: The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.... Agent: Morrison & Foerster LLP

20090068211 - Immunogenically-enhanced polypeptides and related methods: Described herein are immunogenically-enhanced polypeptides, such as KSHV LANA1 polypeptides, related methods of eliciting an immune response to the polypeptides and related nucleotide sequences. Also described herein are novel polypeptides capable of inhibiting degradation and/or retarding synthesis of a protein when attached to or incorporated within that protein along with... Agent: Jesse A. Hirshman, Esq.

20090068213 - Early detection of flaviviruses using the ns1 glycoprotein: The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090068215 - Herpes simplex virus mutant icp0 protein: A mutant virus of herpes simplex virus type 1 (HSV-1) can include a mutant protein involved in replication so as to impair or inhibit replication of HSV-1. The mutant HSV-1 can have a mutation in at least one phosphorylation site of a protein involved in replication in order to inhibit... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090068214 - Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen: The present invention relates to novel methods for producing an enhanced immune response to an immunogen in a subject via the co-administration of a CD40 agonist and a GM-CSF agent.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090068212 - Proteins derived from white spot syndrome virus and uses thereof: Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans.... Agent: Intervet/schering-plough Animal Health Patent Department

20090068218 - Antigens for vaccination against and detection of mycoplasma suis: The present invention relates to antigens for vaccination against and detection of Mycoplasma suis (M. suis) and related haemotrophic Mycoplasma species. Furthermore, the present invention relates to polynucleotides encoding such antigens, vectors containing the polynucleotides, host cells comprising the polynucleotides and/or vectors as well as methods for the treatment of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090068216 - Modified surface antigen: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of... Agent: Panitch Schwarze Belisario & Nadel LLP

20090068217 - Recombinant vaccine for preventing and treating porcine atrophic rhinitis: Disclosed is a recombinant vaccine for porcine atrophic rhinitis. A vaccine is provided which uses a Pasteurella multocida (D:4) outer membrane protein H. The vaccine uses a small size of peptides, so that it exhibits a remarkable activity. In addition, it is possible to provide a vaccine that can be... Agent: Merchant & Gould PC

20090068219 - Anti-wrinkle hormone-type cosmetic composition: A cosmetic anti-aging composition comprising an effective amount of Human Oligopeptide-9 in combination with at least one additional oligopeptide is provided. The composition displays a very surprisingly and highly beneficial synergistic effect for treatment of fine line and wrinkles, skin brightening, skin re-texturization, and/or thickening of the skin, etc.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090068220 - Compositions and methods for diagnosing and treating urinary tract infections: The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.... Agent: Casimir Jones, S.c.

20090068221 - Virus-like particles as vaccines for paramyxovirus: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090068222 - Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type i interferon response: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090068223 - Combination vaccine comprising an attenuated bovine viral diarrhea virus: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090068224 - Method to identify polypeptide toll-like receptor (tlr) ligands: The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The invention also provides polypeptide TLR ligands identified by the methods of the invention. In preferred... Agent: Baker Botts L.L.P.

20090068225 - Compositions and methods for orthopox virus vaccination: The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to an orthopox virus (e.g., vaccinia virus) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising vaccinia virus).... Agent: Casimir Jones, S.c.

20090068226 - Bacterial superantigen vaccines: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using... Agent: U.s. Army Medical Research And Material Command

20090068227 - Use of neurotoxin therapy for treatment of urologic and related disorders: The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.... Agent: Sheridan Ross PC

20090068228 - Method of separating protective components of bordetella pertussis: To provide a method of efficiently separate protective components of Bordetella pertussis. On the basis of differences in adsorbability to calcium phosphate gel formed by adding calcium ions to a Bordetella pertussis culture in the presence of excess phosphate ions, protective components of Bordetella pertussis are separated from the Bordetella... Agent: Foley And Lardner LLP Suite 500

20090068229 - Modified surface antigen: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of... Agent: Panitch Schwarze Belisario & Nadel LLP

20090068230 - Enterohemorrhagic escherichia coli vaccine: Compositions and methods for stimulating an immune response against a secreted enterohemorragic Escherichia coli (EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.... Agent: Woodcock Washburn LLP

20090068232 - Attenuated mycoplasma gallisepticum strains: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein... Agent: Wyeth Patent Law Group

20090068231 - Live attenuated mycoplasma strains: The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type Mycoplasma bacterium of the same species. Also provided are vaccines and vaccination methods... Agent: Wyeth Patent Law Group

20090068233 - Methods and compositions for diagnosis and immunotherapy of pollen allergy: A diagnostic pollen array includes allergens extracted from pollen coat material. Diagnostic pollen arrays are useful to diagnose allergy in individuals, identify novel allergens, identify genetic loci responsible for allergy in hosts, and to develop treatment plans for allergy.... Agent: Barnes & Thornburg LLP

20090068235 - Immunogenic cd19 peptides: The invention provides relatively short immunogenic peptides derived from CD19 antigens, and biologically active variants thereof, which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and... Agent: Foley & Lardner LLP

20090068234 - Methods and compositions for the treatment and prevention of cancer: The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3α/CCL20 or β-defensin mDF2β. The invention further provides cancer vaccines and methods for treating subjects having,... Agent: Edwards Angell Palmer & Dodge LLP

20090068237 - Dry eye treatment: This invention relates to an emulsion composition for the formation of an artificial tear film over the ocular surface of the eye capable of providing mechanical lubrication for the ocular surface while reducing evaporation of fluid therefrom. The emulsion is desirably in the form of a meta stable emulsion and... Agent: Robert G. Rosenthal

20090068236 - Oral cephalotaxine dosage forms: The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations.... Agent: Morgan, Lewis & Bockius, LLP

20090068238 - Cosmetic composition containing elastomers: The present invention relates to a solid anhydrous cosmetic composition comprising at least one non-spherical silicone elastomer and at least one silicone elastomer powder coated with a silicone resin. The invention also relates to a makeup process comprising the application to keratin materials of the said composition, and also to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090068240 - Cosmetic tool: A cosmetic tool characterized in that: its structure is such that the first sheet to fourth sheet are stitched up along their peripheries, with the stitched part prevented from projecting outward along the entire periphery; a powder cosmetic material is filled between the second sheet and third sheet allowing powder... Agent: Knobbe Martens Olson & Bear LLP

20090068239 - Refreshment towel and applied solution: A refreshment towel with applied solution is an apparatus consisting of a carrying agent, most likely a high quality cotton towel or towelette, that has been saturated with an aqueous solution comprised of various ingredients. The resulting saturated towel can be rubbed on a user's skin such that the aqueous... Agent: Smith Frohwein Tempel Greenlee Blaha, LLC

20090068241 - Deposition of metals onto nanotube transparent conductors: This invention is directed to compositions and methods of incorporating metal particles into carbon nanotube films, sheets, and networks. Metal salts that are soluble in water, alcohol, polar organic solvents, and mixtures thereof are used to deposit metal particles onto carbon nanotube films, sheets, and networks. Metal salts increase conductance... Agent: James Remenick Novak Druce & Quigg, LLP

20090068242 - Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache): i

20090068243 - Novel formulations for delivery of antiviral peptide therapeutics: Provided herein are compositions and methods for their administration as therapeutic agents. In particular, provided herein are compositions and their use for the administration of antiviral peptide therapeutics.... Agent: Jones Day

20090068249 - metal alloys for medical devices: A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device.... Agent: Fay Sharpe LLP

20090068247 - Biocompatible devices coated with a tribonectin and methods for their production: The present invention features biocompatible devices having a surface thereof coated with a composition that includes a tribonectin, and methods of making the devices. The tribonectin may, e.g., reduce microbial growth on or attachment to the surface of the biocompatible device.... Agent: Clark & Elbing LLP

20090068246 - Collagen-related peptides and uses thereof: The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof.... Agent: Philip S. Johnson Johnson & Johnson

20090068248 - Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same: e

20090068244 - Polymeric/carbon composite materials for use in medical devices: The invention provides implantable or insertable medical devices, which contain one or more composite regions. These composite regions, in turn, contain polymer and carbon particles. Also, the invention provides composite materials for use in a medical device containing styrene-isobutylene copolymer and carbon nanotubes.... Agent: Mayer & Williams PC

20090068245 - Porous laser sintered articles: The present invention provides selectively laser sintered porous polymeric articles and methods of making and using the same. In one embodiment, a method of the present invention comprises providing a first layer of particles of a first polymeric material, heating selected locations of the first layer to sinter particles of... Agent: Kilpatrick Stockton LLP

20090068250 - Bioresorbable and biocompatible compounds for surgical use: A bioresorbable and biocompatible compound for surgical use is composed of functionalized collagen cross-linked with a glycosaminoglycan.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090068251 - Methods and compositions for promoting wound healing: Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.... Agent: Dechert LLP

20090068252 - Transdermal absorption preparation: A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at... Agent: Edwards Angell Palmer & Dodge LLP

20090068257 - Betulonic and betulinic acid derivatives: The compounds of the present invention may be used for the treatment of cancer or a viral infection. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention. The present invention further provides processes for the preparation of the compounds of the present invention, for example,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090068258 - Caveolin-mimetic peptide for prevention and treatment of pulmonary hypertension and right ventricular hypertrophy: Methods are provided for preventing and treating pulmonary hypertension and right ventricular hypertrophy involving administering to a patient a caveolin peptide coupled to a cell permeating compound such as a cell permeating peptide.... Agent: Amster, Rothstein & Ebenstein LLP

20090068256 - Encapsulation of bioactive complexes in liposomes: This invention provides a method to prepare liposome-encapsulated bioactive agents, such as nucleic acids, comprising complexation of the bioactive agents to reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090068253 - Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione: The invention is the use of a therapeutically effective amount of glutathione (reduced) in a liposome encapsulation for oral administration to improve symptoms of illnesses that are related to viruses and for the treatment and prevention of virus, particularly HHV-6 and EBV, which liposomal encapsulation of glutathione (reduced) is referred... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20090068254 - Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant: A multivalent liposomal composition, preferably a vaccine, comprises liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigens of several serotypes and T-cell dependent protein carrier, such as tetanus toxoid. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.... Agent: Morrison & Foerster LLP

20090068255 - Use of matrix metalloproteinase inhibitors in skin care: The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated... Agent: Fitzpatrick Cella Harper & Scinto

20090068259 - Controlled surface gelling of mucoadhesive polymers on oral mucosa: The present invention relates to an oral composition and method for alleviating the symptoms associated with xerostomia using encapsulated cation-releasing compounds formulated either intimately together or in separate compartments in a composition containing cation-sensitive mucoadhesive polymers.... Agent: Colgate-palmolive Company

20090068260 - Beta-1-selective adrenoceptor blocking agent compositions and methods for their preparation: The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient, optionally also comprising a diuretic such as but not limited to hydrochlorothiazide, and methods of preparing such extended release pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20090068261 - Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles: The invention relates to solid oral pharmaceutical compositions in the form of pellets, mini-tablets, tablets, or capsules, comprising an optionally substituted 2-(pyridylmethylsulfinyl)-1H-benzimidazole, for example esomeprazole, and carrageenan, and optionally one or more excipients. Surprisingly, it has been found that these compositions are stable and rapidly release the active ingredient. The... Agent: Ladas & Parry LLP

20090068262 - Rapid dissolution of combination products: Provided are rapidly dissolving pharmaceutical oral dosage forms of triptans and NSAIDs, processes for the preparation thereof, and methods of treatment therewith.... Agent: Kenyon & Kenyon LLP

20090068263 - Multiple unit compositions: The present invention provides a multiple unit compositions comprising of enteric coated pellets and at least one tablet excipient, wherein each pellet comprises: i) a core comprising active ingredient(s); ii) optionally a separating layer coated on the core; iii) at least two enteric layers comprising of enteric polymers and plasticizer... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090068264 - Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate: Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL).... Agent: Townsend And Townsend And Crew, LLP

20090068265 - Ecklonia cava extracts for alleviating or preventing asthmatic reactions: A method of alleviating or preventing inflammation in an animal is provided. In concrete, the method comprises the step of administering to an animal a composition including an Ecklonia cava extract in an amount effective to suppress SOCS-3 expression in the animal to thereby alleviate or prevent inflammation in the... Agent: Christie, Parker & Hale, LLP

20090068267 - Novel pharmaceutical compositions: The present invention relates to novel lamivudine/cyclodextrin complexes and processes for preparing said complexes. The present invention also relates to novel solid pharmaceutical compositions comprising lamivudine, wherein lamivudine is present in the form of said lamivudine/cyclodextrin complexes. The present invention further relates to processes for preparing said compositions.... Agent: Leydig Voit & Mayer, Ltd

20090068266 - Sirolimus having specific particle size and pharmaceutical compositions thereof: Sirolimus particles having d90 value of from about 2μ to about 10μ have been developed. Further, pharmaceutical composition comprising sirolimus particles having d90 value of from about 2μ to about 10μ have also been developed.... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20090068268 - Melt granulation of a composition containing a calcium-containing compound: A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of... Agent: Edwards Angell Palmer & Dodge LLP

20090068269 - Orally adminstrable opioid formulations having extended duration of effect: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in... Agent: Darby & Darby P.C.

20090068270 - Treatment of degenerated disc with autologous cells: The present invention relates to administering autologous uncultured cells into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090068271 - Embolization particles: Embolic particles, embolic particle chains, and methods for making embolic particles and embolic particle chains are described.... Agent: Fish & Richardson PC

20090068274 - Highly efficient delivery of a large therapeutic mass aerosol: b

20090068273 - Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases: The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090068272 - Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents: Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid. A hydrated silica gel layer having abundant Si—OH functional groups can be formed on... Agent: Perkins Coie LLP Patent-sea

20090068275 - Process for the manufacture of powders of inhalable medicaments: s

20090068277 - Pharmaceutical composition comprising lipase inhibitor and lipophilic oil absorbent and oral formulation prepared therefrom: This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090068276 - Pharmaceutical compositions: The present invention relates to new pharmaceutical formulations comprising pharmaceutically active agents which can induce one or more involuntary coughs in a patient when administered as conventional formulations and/or via conventional routes. Formulations are provided comprising a cough-inducing pharmaceutically active agent, wherein the formulation may be administered by pulmonary inhalation... Agent: Davidson, Davidson & Kappel, LLC

20090068278 - Use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy: The invention also concerns a method for the protection or treatment of skin and hair damages of a mammal caused by chemotherapy. The invention further relates to a kit for the protection or treatment of hair damages caused by chemotherapeutic treatment consisting of a topical composition comprising microparticles together with... Agent: Millen, White, Zelano & Branigan, P.C.

20090068279 - Microspheres with surface projections: Methods of making polymer particles, as well as related particles, compositions, and methods are disclosed.... Agent: Fish & Richardson PC

20090068280 - Controlled release interferon drug products and treatment of hcv infections using same: The invention relates to controlled release formulations comprising a microparticle comprising a biodegradable polymer and one or more interferon compounds and methods of using the formulations.... Agent: Brinks, Hofer, Gilson & Lione

20090068281 - Composition, functional food and pharmaceutical composition for improvement in obesity: A composition for improving obesity is disclosed. The composition contains a natural ingredient free of side effects in daily intake as an active ingredient. The composition is capable of remarkably reducing body fat, as compared with a conventional ingredient which is derived from a natural ingredient as an active ingredient,... Agent: Birch Stewart Kolasch & Birch

20090068282 - Use of metal complex compounds as oxidation catalysts: c

20090068284 - Method for treating menorrhagia: A delivery vehicle for a silver ion source such as silver nitrate and the like, suitable for use in the treatment of menorrhagia, comprises a plurality of physiologically inert beads bearing a tissue cauterizing amount of a silver ion source. Preferably the beads are made of a physiologically inert polymer,... Agent: Olson & Cepuritis, Ltd.

20090068283 - Silver-based inorganic antimicrobial agent and antimicrobial product: d

20090068285 - Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate: The present invention provides novel biomaterials comprising one or more of Mg, Zn and F ions in a carbonate-containing biphasic calcium phosphate (BCP) system. The biomaterial may contain Mg, Zn, F, Mg and Zn, Mg and F, Zn and F, or Mg, Zn and F. The biomaterial may be substantially... Agent: Klauber & Jackson

20090068286 - Method of treating cancer by administration of 5-substituted nucleosides: The invention relates to methods of administration of at least one overexpression inhibitor of DNA repair genes and/or oncogenes (e.g., (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU), or a prodrug, or salt thereof) to increase the cytotoxic effect of a cytostatic or cytotoxic chemotherapeutic agent during and/or after chemotherapy, e.g., in the treatment of cancer.... Agent: Greenblum & Bernstein, P.L.C

20090068287 - Novel topical formulations of flucytosine and uses thereof: The invention relates to topical formulations and methods of use of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains... Agent: Richard D. Wood

20090068288 - Topical antiseptic veterinary solution: This invention relates to a veterinary antiseptic solution having three sources of iodine including elemental iodine, iodide salt and iodophor. The solution also includes at least one solvent such as alcohol, glycol or water. The solution is below the threshold concentration for elemental iodine of the List I controlled substances.... Agent: Pauley Petersen & Erickson

20090068289 - Formulation for menopausal women: The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same.... Agent: Kv Pharmaceutical Company

20090068290 - Bifeprunox doses for treating schizophrenia: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090068293 - Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof: Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include... Agent: Wilson Sonsini Goodrich & Rosati

20090068294 - Estrogenic extracts of rheum palmatum l of the polygonaceae family and uses thereof: Extracts of various species of the Polygonaceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Rheum palmatum L of the Polygonaceae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor... Agent: Wilson Sonsini Goodrich & Rosati

20090068291 - Plant extracts and compositions comprising extracellular protease inhibitors: The present invention provides a plant derived extract comprising inhibitory activity against one or more extracellular proteases which degrade human tissue matrix. Moreover, the amount of inhibitory activity in an extract can be increased by stressing the plant prior to forming an extract. These extracts are each prepared by a... Agent: Gary M. Nath The Nath Law Group

20090068292 - Therapeutic herb cosmetic composition: The current invention discloses an herb composition to treat burn, sun burn, physical injury, dermatitis, or to promote skin stem cell proliferation, increase collagen synthesis, increase epidermal thickness, and increase desquamation of normal skin resulting in smoother, younger looking skin. The composition comprises of herb extract from Polygonum cuspidatum; Phellodendron... Agent: Lixian Jiang

20090068295 - Composition for treating cancer and method of using the same: The present invention provides a composition, which includes an effective amount of DNA damaging agent and an effective amount of tea polyphenols. Particularly, the preferred DNA damaging agent is 5-Fluorouracil (5-FU), and the preferred tea polyphenols is Epigallocatechin gallate (EGCG).... Agent: Bacon & Thomas, PLLC

20090068296 - Composition for improved production, health and fertility traits: This invention relates to products and methods for improving sensory qualities of meat obtained from livestock. In particular, this invention relates to products and methods for reducing off-odors and off-tastes in meat from uncastrated male pigs (boar taint) or from other livestock fed on pasture. According to the invention, this... Agent: Lowe Hauptman Ham & Berner, LLP

20090068297 - Estrogenic extracts of scuttelaria barbata d. don of the labiatae family and uses thereof: Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Scuttelaria barbata D. Don of the Labiatae Family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis... Agent: Wilson Sonsini Goodrich & Rosati

20090068298 - Estrogenic extracts of astragalus membranaceus fisch. bge. var. mongolicus bge. of the leguminosae family and uses thereof: Estrogenic extracts of Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments,... Agent: Wilson Sonsini Goodrich & Rosati

20090068299 - Estrogenic extracts of pueraria lobata willd. ohwi of the leguminosae family and uses thereof: Extracts of various species of the Leguminosae family have estrogenic properties. For example, aqueous and ethanolic extracts of Pueraria lobata Willd. Ohwi of the Leguminosae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis... Agent: Wilson Sonsini Goodrich & Rosati

20090068300 - Pre- and post-workout formulations processes and supplement products thereby: An improved process for manufacturing, using, and optimizing performance of a mammal using a pre- and post-workout supplement discloses important ingredients, formulations, and dosage protocols. Elite athletes, average consumers, and select groups of those challenged can be benefited by products by the disclosed processes, as evinced by the performance of... Agent: Greenberg Traurig LLP (la)

20090060836 - Derivatives of 2-nitro-1,3-imidazole coupled to amino acids and deoxyribose useful for the detection of hypoxic biological tissue: The present invention relates to a 2-nitroimidazole derivative, a diagnostic pharmaceutical composition which contains such 2-nitroimidazole derivative, the use of the 2-nitroimidazole derivative for the detection of hypoxic biological tissue as well a method for the detection of hypoxic biological tissue by the use of the 2-nitroimidazole derivative.... Agent: Knobbe Martens Olson & Bear LLP

20090060837 - Cobalamin conjugates useful as antitumor agents: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.... Agent: Fish & Richardson P.C.

20090060838 - Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies: Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed... Agent: Proteotech, Inc.

20090060839 - Gold nanoparticle conjugates and uses thereof: The disclosure generally relates to formation of polymers grafted to or polymerized from the surface of gold nanoparticles. The polymers are functionalized to include therapeutic agents and/or targeting agents at their surface, thereby allowing both therapeutic and targeting compounds to be directed to specific cells in a patient.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090060840 - Lanthanide nanoparticle conjugates and uses thereof: The present disclosure is directed generally to lanthanide nanoparticle conjugates, such as gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, conjugation to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090060841 - Apparatus and method for combined use of variable flip angles and centric phase encoding in hyperpolarized 13c imaging: A system and method for MR imaging includes a magnetic resonance imaging (MRI) system having a plurality of gradient coils positioned about a bore of a magnet, and an RF transceiver system and an RF switch controlled by a pulse module to transmit RF signals to an RF coil assembly... Agent: Ziolkowski Patent Solutions Group, Sc (gems)

20090060842 - Method for diagnosis and treatment of prostatitis: In a method for diagnosis and treatment of a patient with regard to prostatitis, a differential diagnosis of prostatitis versus prostate cancer and/or BPH is conducted on a patient using a cost-effective diagnosis method. Given diagnosed prostatitis, a cost-effective decision test is implemented on the patient to determine whether the... Agent: Schiff Hardin, LLP Patent Department

20090060845 - Diagnosis substance for application in a method to diagnosis pathological tissue and a method for production of such a diagnosis substance: A diagnosis substance for application in a method for diagnosis of pathological tissue, contains at least one virus population with virus particles specifically binding to target molecules typical of a specific pathological tissue, with a label that is detectable with the use of a detection device being bound to the... Agent: Schiff Hardin, LLP Patent Department

20090060844 - Method and contrast agent for imaging a prostate tumor: In a method for imaging a prostate tumor in which a contrast agent that can be distributed via the circulatory system is administered to the patient, the contrast agent contains at least one type of biomarkers which are bound to a ferromagnetic particle and specifically bind to a target molecule... Agent: Schiff Hardin, LLP Patent Department

20090060846 - Nanoparticles having reactive ester groups covalently coupled thereto and related methods: A particle having a core and a surface to which are covalently coupled a plurality of reactive ester groups. Methods for using the particle to prepare a particle having one or more of a plurality of a targeting agent, a diagnostic agent, or a therapeutic agent covalently coupled thereto.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090060847 - Contrast agent for ultrasound examination of the prostate and method to diagnose prostate cancer: A contrast agent for ultrasound examination of the prostate has contrast-intensifying particles on an exterior of which at least one binding molecule is present that specifically binds to CEACAM-1. In a method for ultrasound examination of the prostate, such a contrast agent is administered to the patient and a sonography... Agent: Schiff Hardin, LLP Patent Department

20090060843 - Non-invasive in vivo imaging and methods for treating type i diabetes: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090060848 - Pharmaceutical composition which reduces or eliminates drug abuse potential: A pharmaceutical composition which reduces or eliminates the drug abuse potential of central nervous system stimulant comprising: (a) a drug selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and (b) a gel forming polymer wherein the gel forming polymer is a polymer that forms a gel... Agent: Novartis Corporate Intellectual Property

20090060849 - Personal care compositions comprising certain dye-polymer complexes: The present invention relates to personal care compositions comprising certain dye-polymer complexes. Additionally, methods for coloration of personal care compositions using said dye-polymer complexes are disclosed.... Agent: Joann Villamizar Ciba Corporation/patent Department

20090060850 - Ericacea extracts for combating skin aging: Extracts of plants of the Ericacea family are administered to individuals to combat the signs of aging of the skin, e.g., wrinkles and fine lines, for example by inhibiting the expression of metalloproteases, by inhibiting collagen degradation, or by inhibiting UV-induced skin degradation.... Agent: Buchanan, Ingersoll & Rooney PC

20090060853 - Aminophenylbenzothiazole compounds: t

20090060852 - Compounds, formulations and methods for reducing skin wrinkles, creasing and sagging: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly... Agent: Hoffmann & Baron, LLP

20090060851 - Use of idebenone for the preparation of a topically-applied depigmentation composition and corresponding composition: The invention relates to the use of idebenone for the preparation of a topically-applied composition which is intended to inhibit melanogenesis, to reduce cutaneous coloration or to brighten same and/or produce cutaneous depigmentation. More specifically, the invention relates to a topically-applied composition comprising a cosmetic, pharmaceutical and/or dermatologically-effective amount of... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090060854 - Dermatological compound: A topically-applied composition for the treatment of the dermal and subcutaneous skin layers combines selected sulfonated glycosaminoglycans and two anti-oxidizing compounds in a pharmaceutically acceptable carrier. A constituent to treat damage due to ultraviolet A and/or B light can be added to the composition. Differing formulations are provided for daytime... Agent: Law Offices Of Jerry A. Schulman

20090060855 - Dermatological compound: The present disclosure relates to compositions for the bleaching of keratinous fibers comprising at least one peroxygenated salt and at least one non-volatile liquid branched ester of a carboxylic acid, the solidification point of which is below 4° C., chosen from the compounds with the following structure: R1—CO—O—R2, wherein R1... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090060856 - Colorant composition for skin cosmetics, foundation containing the same, and method of makeup application: The object of the invention is to provide a colorant composition for skin cosmetics, that can provide a natural texture while retaining hiding power, a foundation containing the same, and a method of makeup application. A colorant composition for skin cosmetics of the present invention is characterized in that the... Agent: Rankin, Hill & Clark LLP

20090060857 - Lip gloss: Embodiments of inventive subject matter described herein include a lip gloss comprising: a sugar gel matrix that includes stearoyl inulin and an ester or ether of formula R(1) COOR(2) in which R(1) is a residue of a fatty acid including from 6 to 29 carbon atoms and R(2) is a... Agent: Schwegman, Lundberg & Woessner, P.A.

20090060858 - Haircare composition: Hair care compositions contain from 0.1 to 12 weight percent of a silicone copolymer or saponification product thereof, prepared from silicones, at least 10% of which contain polymerizable groups, 0.5-14% of hydrophilic comonomers, and 30-99.9% of hydrophobic comonomers. The compositions exhibit good hair care properties.... Agent: Brooks Kushman P.C.

20090060859 - Imidazolium alkyl (meth)acrylate polymers: The present invention relates to the use of imidazolium alkyl(meth)acrylate homo- and copolymers in cosmetic preparations and to the corresponding cosmetic preparations.... Agent: Connolly Bove Lodge & Hutz LLP

20090060860 - Beta-cyclodextrins as nucleating agents for poly(lactic acid): The use of β-CDs as nucleating agents for PLA to provide an increase in polymer crystallinity is described. The improvement in increased crystallinity is related to the percentage of β-CDs used. For the analyzed films, crystallinity was approximately 1.47% in the absence of a nucleating agent, and approximately 17.85% in... Agent: Howard & Howard Attorneys PLLC

20090060863 - Derivatives of growth hormone and related proteins: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Sheridan Ross PC

20090060865 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Dnax Research Inc. Legal Department

20090060864 - Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein... Agent: Olson & Cepuritis, Ltd.

20090060862 - Pegylation by the dock and lock (dnl) technique: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence... Agent: Immunomedics, Inc.

20090060866 - Phosphadiazine hcv polymerase inhibitors i and ii: Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host... Agent: Jones Day

20090060867 - Phosphadiazine hcv polymerase inhibitors iii and vi: Provided herein are phosphadiazine polymerase inhibitor, for example, of Formula III, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Jones Day

20090060861 - Stabilized polypeptide formulations: The present invention relates to a pharmaceutical formulation comprising a polypeptide and a buffer selected from the group consisting of diethylmalonic acid, trimellitic acid, shikimic acid, glycinamid, 2-amino-2-methyl-1,3-propanediol (AMPD) and tetraethylammonium (T.E.A.) or salts thereof. Further more the invention relates to a method for improving stability of a polypeptide in... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090060871 - Administration of agonist-antagonist in opioid-dependent patients: A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby reducing craving for the opioid in the patient. An opioid agonist-antagonist is administered in a patient needing an average adherence to... Agent: Houston Eliseeva

20090060868 - Alpha-msh therapies for treatment of autoimmune disease: Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment... Agent: Fulbright & Jaworski, L.L.P.

20090060869 - Ejection liquid, ejection method, method of making droplets from liquid, cartridge and ejection device: The present invention provides a liquid composition, as an ejection liquid used for stably ejecting liquid droplets, including at least one kind of a protein and a peptide, and a compound having a betaine skeleton by application of thermal energy to the liquid; a method of making droplets form the... Agent: Fitzpatrick Cella Harper & Scinto

20090060870 - Methods and means for the treatment of hpv induced intraepithelial neoplasia: The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090060872 - Phosphadiazine hcv polymerase inhibitors v: Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas V, V′, I″, II″, or Va, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Jones Day

20090060874 - Bicyclic pyrrolidine derivatives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090060873 - Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris: The present invention overcomes limitations of the prior art by providing new compounds and methods for the treatment of conditions, such as neurodegenerative diseases (e.g., multiple sclerosis), psychiatric disorders (e.g., psychosis, bipolar disorder, depression, neuropathic pain), conditions involving CNS-mediated chronic pain, spinal cord injuries, and other diseases or injuries.... Agent: Fulbright & Jaworski L.L.P.

20090060875 - Hcv vaccines for chronic hcv patients: The invention discloses the use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections.... Agent: Fulbright & Jaworski L.L.P.

20090060889 - Ii-rnai involved ii suppression in cancer immunotherapy: Provided are compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated. The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has... Agent: Kevin Farrell Pierce Atwood

20090060888 - Regulated transcription of targeted genes and other biological events: o

20090060878 - Oral compositions, products and methods of use: The present invention comprises an oral composition. More particularly to a method of treating and preventing a respiratory tract infection and providing energy, relieving stress, and mood enhancing benefits to a human comprising: the steps of administering to a human a composition comprising from about 450 IU to about 500,000... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090060879 - Oral compositions, products and methods of use: The present invention comprises an oral composition. More particularly to a method of treating and preventing a respiratory tract infection and providing energy, relieving stress, and mood enhancing benefits to a human comprising: the steps of administering to a human a composition comprising from about 450 IU to about 500,000... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090060876 - Orally used compatible solutes containing agents: The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal... Agent: Berliner & Associates

20090060877 - Use: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering... Agent: Steptoe & Johnson LLP

20090060880 - Biocontrol of varroa mites: A biopesticide formulation using isolates of the fungus Beauveria bassiana has been developed, which can be used to control arachnid infestations of honeybee hives. The formulation is particularly useful for controlling infestations of Varroa destructor in honey bee hives.... Agent: Usda, Ars, Ott

20090060881 - Gamma secretase inhibitor for treatment of herpesvirus infection: This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby arresting the growth of the infected cells.... Agent: Pearl Cohen Zedek Latzer, LLP

20090060883 - Composition for promotion of bone growth and maintenance of bone health: The present invention relates to a composition for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat or a medicament; and a method of promoting bone growth... Agent: Bell, Boyd & Lloyd LLP

20090060885 - Composition for treatment of articular cartilage damage: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem... Agent: Sughrue Mion, PLLC

20090060884 - Concentration of stem cells obtained during orthopaedic surgeries: Methods for isolating and concentrating bone marrow stromal cells drawn from various surgical sites (for example, the proximal humeral head during rotator cuff repair, or the distal femur during ACL surgery) during arthroscopic or open orthopaedic surgery. The pluripotent cells obtained from the bone marrow aspirate can then be reimplanted... Agent: Dickstein Shapiro LLP

20090060887 - Method for treating the pancreas of a human patient: The invention involves a method for treating a pancreas of a human patient by rejuvenating and restoring function of such pancreas by the steps of locally inserting a growth factor, such as stem cells and germinal cells, into the body of the patient into or around the pancreas and thereby... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20090060882 - Method of treating mouse carrying human hepatocytes: Human adult hepatocytes are transplanted into an immunodeficient hepatopathy mouse and then human growth hormone is administered to the mouse to thereby elevate twice or more the replacement ratio by the human adult hepatocytes having been transplanted. Further, human growth hormone is administered to an immunodeficient hepatopathy mouse carrying human... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090060886 - Transluminal application of adult stem cells for body organ tissue repair: A method for repairing tissue of a selected organ from among heart, brain, liver, pancreas, kidney, glands, and muscles in a patient's body. Adult stem cells that have the capability to repair tissue of the selected organ are recovered by harvesting from the patient's body. The harvested stem cells are... Agent: Hanley, Flight & Zimmerman, LLC

20090060890 - Selective cytopheresis devices and related methods thereof: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.... Agent: Casimir Jones, S.c.

20090060892 - Agents for suppressing hepatic fibrosis: The present inventors discovered for the first time that hepatic fibrosis could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, fibrosis of liver tissues can be suppressed by administering chondroitinase ABC, a chondroitin sulfate proteoglycan-degrading enzyme, or by using siRNA to suppress the expression... Agent: Bozicevic, Field & Francis LLP

20090060891 - High concentration self-microemulsifying coenzyme q10 preparations for nutritional use: A method and composition are presented for enhancing the dissolution and bioavailable properties of CoQ10 nutritional supplements and/or therapeutic agents for a human being and other mammals. The method includes preparing an anhydrous self-microemulsifying base composition by combining: CoQ10, a water-immiscible, and a non-ionic surfactant, containing polyethylene glycol. For an... Agent: Jay P. Hendrickson

20090060893 - Methods for enlarging the diameter of a biological conduit in a human subject: The invention provides methods for treating a an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s)... Agent: Fried, Frank, Harris, Shriver & Jacobson LLP

20090060894 - Treatment to aid in the metabolism of alcohol: Alcohol intoxication is a serious problem. Many individuals are more sensitive to alcohol intoxication and placed at a decided disadvantage in social drinking situations. What is proposed is a way to facilitate alcohol metabolism in individuals who have consumed alcohol by the administration of enzymes to speed the alcohols metabolism.... Agent: John C. Somberg, Md

20090060895 - Compositions and methods of using chondroitinase abci mutants: The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.... Agent: Pepper Hamilton LLP

20090060896 - Gene repair involving in vivo excision of targeting dna: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090060897 - Systems for enlarging the diameter of a biological conduit in a human subject: The invention provides systems for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have... Agent: Fried, Frank, Harris, Shriver & Jacobson LLP

20090060899 - Composition of organic compounds: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the Aβ-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the... Agent: Novartis Corporate Intellectual Property

20090060901 - Detoxification method: The present invention provides a protein toxoid for use in a method of treating the human or animal body by therapy, wherein all cysteine residues in said protein toxoid which are free under reversibly denaturing conditions have been alkylated.... Agent: Fulbright & Jaworski, LLP

20090060898 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an... Agent: Keown & Zucchero, LLP

20090060902 - Methods and compositions for regulating t cell subsets by modulating transcription factor activity: Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of a transcription factor, in particular the proto-oncoprotein c-Maf, that regulates expression of the Th2-associated cytokine gene are disclosed. Methods for modulating development of T helper type 1 (Th1) or T... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090060900 - Methods for screening compounds that modulate lipid metabolism: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides,... Agent: Howrey LLP - Dc

20090060903 - Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same: Pharmaceutical compositions comprising anti-teratogenic agents are disclosed. Additionally, pharmaceutical compositions comprising anti-neoplastic agents and anti-teratogenic agents are disclosed. Methods of assessing the teratogenicity of a compound are disclosed. The present invention further comprises applications of the aforementioned compositions and methods.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090060905 - Use of 15-lipoxygenase inhibitors for treating obesity: The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences.... Agent: Hunton & Williams LLP Intellectual Property Department

20090060904 - Vegetarian protein a preparation and methods thereof: The invention relates to methods of producing Protein A without contamination of the Protein A by animal products. The invention also relates to a vegetarian fermentation media in which Staphylococcus aureus is grown to produce a vegetarian Protein A. The invention further relates to a vegetarian Protein A and the... Agent: Mallinckrodt Inc.

20090060906 - Anti-il-13 antibody formulations and uses thereof: Formulations suitable for treatment of disorders associated with undesirable expression or activity of IL-13 are provided.... Agent: Wilmerhale/wyeth

20090060907 - Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell... Agent: Davidson, Davidson & Kappel, LLC

20090060909 - Antibody antagonists of ve-cadherin without adverse effects on vascular permeability: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090060913 - Combination therapy with type i and type ii anti-cd20 antibodies: e

20090060910 - Covalent diabodies and uses thereof: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which... Agent: Edell, Shapiro & Finnan, LLC

20090060914 - Deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection: This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21,... Agent: Morgan & Finnegan, L.L.P.

20090060911 - Enhancement of antibody-mediated immune responses: The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region... Agent: Pepper Hamilton LLP

20090060908 - Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090060912 - Small molecule pi 3-kinase inhibitors and methods of their use: e

20090060915 - Polypeptide, vaccine and use thereof: The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising a whole angiomotin molecule or a fragment thereof which may be used to generate immune responses... Agent: Fish & Richardson P.C.

20090060917 - Carbamate stereoisomer: e

20090060916 - Ligands that bind il-4 and/or il-13: Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.... Agent: Mcdermott Will & Emery LLP

20090060918 - Method of treating or preventing an il-1 related disease or condition: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and... Agent: Bell, Boyd & Lloyd, LLP

20090060919 - Binding members for ige molecules: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.... Agent: Astrazeneca R&d Boston

20090060920 - Desacyl ghrelin antibodies and therapeutic uses thereof: A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment... Agent: Eli Lilly & Company

20090060921 - Glycan-optimized anti-cd20 antibodies: Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached... Agent: Alston & Bird LLP

20090060922 - Acetamide stereoisomer: y

20090060923 - Method of treating or preventing an il-1 related disease or condition: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and... Agent: Bell, Boyd & Lloyd, LLP

20090060924 - Anti-sclerostin antibodies: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human... Agent: Eli Lilly & Company

20090060926 - Medicine for treatment of carcinoma: A medicine for treatment of a carcinoma which can be supplied to the carcinoma via the circulatory system, contains two active components coupled to one another. The first active component is formed of at least one coupling molecule that specifically tethers to a target molecule formed by the cancer tissue.... Agent: Schiff Hardin, LLP Patent Department

20090060925 - Rage fusion proteins and methods of use: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity... Agent: Cooper & Dunham, LLP

20090060927 - Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination: The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth,... Agent: Helen C. Lockhart Wolf, Greenfield & Sacks, P.C.

20090060928 - Topical toll like receptor ligands as vaccine adjuvants: The present invention provides a method for increasing immunological response to a vaccine, comprising administering the vaccine subcutaneously to a patient in need thereof; anti administering a topical composition containing an amount of a toll like receptor ligand effective to increase immune response of the patient to the vaccine.... Agent: Cooper & Dunham, LLP

20090060930 - Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes,... Agent: Mckee, Voorhees & Sease, P.L.C

20090060931 - Pharmaceutical composition for treating or preventing ovarian cancer: The invention relates to therapeutic and prophylactic treatment of ovarian cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of an ovarian tissue cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090060929 - Transfection complexes: e

20090060933 - Proteases producing an altered immunogenic response and methods of making and using the same: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention... Agent: Genencor International, Inc. Attention: Legal Department

20090060934 - S. agalactiae antigens i & ii: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.... Agent: Fulbright & Jaworski L.L.P.

20090060932 - Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans: The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing Borrelia. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia burgdorferi OspC families A, B, I and K. In... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090060935 - Amebiasis vaccine: An isolated protein fragment containing an epitope which is specific for E. histolytica and is commonly shared by all polymorphic strains of E. histolytica is provided, and which exhibits immunogenicity in the host, and comprises an amino acid sequence containing amino acid sequence 603-1088 of SEQ ID NO: 2, and... Agent: Hovey Williams LLP

20090060936 - Ii-key/her-2/neu hybrid cancer vaccine: Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of... Agent: Kevin Farrell Pierce Atwood

20090060937 - Immunostimulatory oligonucleotides and uses thereof: wherein X1 is C, T, G or A (preferably T or C); wherein X2 is C, T, G or A; wherein X7 is C, T, G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that,... Agent: Darby & Darby P.C.

20090060938 - Polyvalent conjugate vaccine for cancer: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090060939 - Compositions and methods for treating allergies, auto-immune diseases, and improving skin condition by ganoderma lucidum (reishi) polysaccharides: A method for treating an allergy by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating an allergy by first purifying Ganoderma lucidum extract into at least... Agent: Greenberg Traurig LLP (la)

20090060940 - Compositions and methods for treating psoriasis by ganoderma lucidum (reishi) polysaccharides: A method for treating psoriasis by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating psoriasis by first purifying Ganoderma lucidum extract into at least one fraction,... Agent: Greenberg Traurig LLP (la)

20090060941 - Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols: A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes... Agent: Knobbe Martens Olson & Bear LLP

20090060942 - Detoxification composition and method of detoxifying the body: The present invention provides a detoxification composition including alginate, and ulva rigida extract. The present invention further provides a method of detoxifying and cleansing the human body of mutagens, and toxins; reducing cholesterol levels; and preventing or protecting against colon cancer.... Agent: Amin Hallihan, LLC

20090060943 - Syndrome x composition and method of lowering blood pressure and glycemic index: The present invention provides a composition including alginate, seaweed fiber, piperine and potassium citrate for lowering blood pressure, lowering glycemic index, and alleviating conditions associated with Syndrome X. The present invention also provides a method of lowering blood pressure, lowering glycemic index and alleviating conditions associated with Syndrome X. The... Agent: Amin Hallihan, LLC

20090060944 - Enhancer of the effect of adrenocorticoid,comprising gum arabic: This invention provides an enhancer of the effect of adrenocorticoid on nephritis without enhancement of the undesirable side-effects of the said adrenocorticoid, comprising the water-soluble gum obtained from the stem and/or branch of Acacia species, e.g., Gum Arabic. The combination of the adrenocorticoid and the said water-soluble gum enhances the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090060945 - Integration of meningococcal conjugate vaccination: Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as... Agent: Novartis Vaccines And Diagnostics Inc.

20090060946 - Activation of antigen-specific t cells by virus/antigen-treated dendritic cells: The present invention relates to a T cell activating agent containing dendritic cells (DC) treated with virus-treated antigen and/or dendritic cells treated separately with virus and antigen, which may be used as a vaccine to stimulate an immune response in a patient obtainable by the activation of antigen-specific T cells... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090060948 - Cationic lipid-mediated enhancement of nucleic acid immunization of cats: The present invention relates to a method to introduce a nucleic acid molecule into a fetid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune... Agent: Heska Corporation Legal Department

20090060947 - Immunological compositions: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).... Agent: Patrick J. Halloran, Ph.d., J.d

20090060949 - Flu vaccines and methods of use thereof: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.... Agent: Greenberg Traurig, LLP

20090060950 - Method for producing viral vaccines: i

20090060951 - Dna vaccine for koi herpes virus (khv) disease: The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an expression vector comprising the DNA as an active ingredient.... Agent: King & Spalding

20090060952 - Production of the lipidated form of the peptidoglycan-associated liproproteins of gram-negative bacteria: The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a plasmid. The host cell is then cultured under conditions such that... Agent: Wyeth Patent Law Group

20090060953 - Methods for using tetanus toxin for beneficial purposes in animals (mammals): Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in... Agent: Omri M. Behr

20090060954 - Recombinant bcg vaccine: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090060956 - Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity): An agent for reducing the useable calorie content of food is described which contains a compound effecting the dehydrogenation of fructose to 5-keto-D-fructose. In addition, a combination agent is described which also contains a compound that converts glucose to fructose. These agents can be used in particular in the therapy... Agent: Heslin Rothenberg Farley & Mesiti PC

20090060955 - Drug delivery vehicle that mimics viral properties: A drug delivery vehicle for targeted delivery of a drug mimics viral properties of size, capsid-like protein capsule, cell-specific entry, toxin release, destruction of infected cells, and migration to neighboring cells. This vehicle, termed a virogel, contains a hydrophobic polymeric core, a hydrophilic inner shell, a hydrophilic outer shell, and... Agent: Alan J. Howarth

20090060957 - Oral compositions: A multi-phase oral composition, wherein at least one phase has a filling viscosity from about 1.5 to about 5.0 Pa·s at a shear rate of 1000/sec and an after-filling viscosity from about 160 to about 190 Pa·s at a shear rate of 4/sec, and wherein the phases form a visual... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090060962 - Cosmetic use of bifidobacterium species lysate for the treatment of dryness: Cosmetic use of an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species and/or one of its fractions in treating and/or preventing dryness and/or associated disorders of a keratinous substance.... Agent: Oliff & Berridge, PLC

20090060959 - Hydrous powdery cosmetic preparation: A water-containing powdery cosmetic preparation comprises (a) hydrophobic particles having a surface area of at least 80 m2/g, (b) plate-like particles comprising a polymer obtained by polymerizing or copolymerizing one or more types of monomers selected from the group consisting of styrenes, methacrylates, and acrylates, and (c) an aqueous component,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090060958 - Oral care strip or tape and methods of use and manufacture thereof: This invention relates to oral care composition, methods of use and methods of manufacture thereof in the form of a toothtape that can be used to brush or clean teeth and the oral cavity. Particularly, the invention relates to a non-traditional dentifrice that comes in the form of a tape... Agent: Colgate-palmolive Company

20090060960 - Preparation containing barium sulfate: The invention relates to a preparation containing barium sulfate, a method for the production thereof, and the use thereof.... Agent: Fulbright & Jaworski, LLP

20090060961 - Spongelike structure and powder, as well as process for producing the same: An object of the present invention is to provide a spongelike structure or a powder having fibers three-dimensionally arranged therein with high dispersibility, whose apparent density can be designed depending on the purpose or utility, as well as a process producing them. A fiber dispersion in which fibers having a... Agent: Kubovcik & Kubovcik

20090060963 - Wearing article capable of promoting human health: A wearing article includes an article element and a fastening mechanism. The article element includes at least one pack unit that has a fabric housing and a flexible pad body fitted into the fabric housing and including a thin elastic matrix of an elastic material and a plurality of functional... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20090060964 - Animal repellant and associated dispenser: A dispenser for an animal repellant including: a housing, wherein the housing includes a chamber for containing a spool; a spool, wherein the spool is associated with the chamber of the housing, and wherein the spool is associated with an animal repellant; and wherein the animal repellant includes a substrate,... Agent: King & Partners, PLC

20090060965 - Water dispersible formulation for delivery of biocontrol fungi to reduce aflatoxin: A formulation containing conidia of non-toxigenic strains of fungi is a useful biocontrol agent for preventing toxin contamination in agricultural commodities, especially those for human and animal consumption such as peanuts, corn, cotton and tree nuts. The formulation of the invention is a water dispersible granule formulation suitable for spraying... Agent: Usda, Ars, Ott

20090060966 - Pesticidal composition: A pesticidal composition including a microcapsule in which an oil containing a pesticidal active ingredient and an organic solvent is covered with a wall material made of a thermosetting resin, a sorbitan fatty acid ester, a thickener, and water is provided. The pesticidal composition has elution performance suited for an... Agent: Foley And Lardner LLP Suite 500

20090060967 - Antimicrobial fiber and method for producing the same thereof: An object of the present invention is to provide an antimicrobial fiber having a diameter of approximately 10 to 30 μm that is superior in surface smoothness, transparency, and others, and a method for producing the same thereof. Provided is an antimicrobial fiber, comprising a transparent resin, an antimicrobial glass,... Agent: Kanesaka Berner And Partners LLP

20090060968 - Inhibitors of phosphatases: The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases.... Agent: Vertex Pharmaceuticals Inc.

20090060969 - Porous biodegradable polymeric materials for cell transplantation: Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted... Agent: Clark & Elbing LLP

20090060973 - Compositions and methods for coating medical implants: Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.... Agent: Seed Intellectual Property Law Group PLLC

20090060970 - Compositions and methods of administering paclitaxel with other drugs using medical devices: Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or... Agent: Squire, Sanders & Dempsey LLP

20090060975 - Containment system for delivery of biological products and method of surgery: Methods and systems for delivering biological products such as bone marrow aspirate (BMA) to different surgical sites during surgery (for example, arthroscopic surgery). The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble... Agent: Dickstein Shapiro LLP

20090060972 - Device and method for cell grafting: A device for cell grafting is disclosed. The device comprises a compartment enclosed by a semipermeable envelope made at least in part of nonwoven polymer fibers, and at least one inlet port formed in the envelope. The inlet port(s) are accessible from the exterior of the envelope and configured for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090060977 - Devices, systems and methods for treating benign prostatic hyperplasia and other conditions: Devices, systems and methods for compressing, cutting, incising, reconfiguring, remodeling, attaching, repositioning, supporting, dislocating or altering the composition of tissues or anatomical structures to alter their positional or force relationship to other tissues or anatomical structures. In some applications, the invention may be used to used to improve patency or... Agent: Steptoe & Johnson - Neotract

20090060974 - Methods of arthroscopic osteochondral resurfacing: Methods of arthroscopic resurfacing of anatomical tissue utilizing a biological component strengthened with glue or similar material. The biological component is selected from the group consisting of blood, blood components, PRP, bone marrow aspirate (BMA) and autologous conditioned plasma (ACP). The biological component/glue composition may be inserted (by injection and/or... Agent: Dickstein Shapiro LLP

20090060971 - Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent: Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation.... Agent: Medtronic Spinal And Biologics Attn: Noreen Johnson -IPLegal Department

20090060976 - Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but... Agent: Ropes & Gray LLP

20090060979 - Controlled release of biologically active compounds: The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.... Agent: Feldmangale, P.A.

20090060978 - Resorbable barrier micro-membranes for attenuation of scar tissue during healing: Resorbable lactide polymer micro-membranes are disclosed. The micro-membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010... Agent: Kenton R. Mullins Stout, Uxa, Buyan & Mullins, LLP

20090060980 - Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon: Disclosed are novel methods of treatment for retinal diseases and conditions including age-related macular degeneration, genetic-based retinal degenerations and retinal detachment. A novel glycan binding protein thought to be a cell surface receptor has been discovered in the retina. The retinal glycan binding receptor is shown to play an important... Agent: Margaret J. Mclaren, P.A. Mclaren Legal Services

20090060981 - Contact lens based bioactive agent delivery system: A bioactive agent delivery system comprising an optically transparent contact lens having dispersed therein (1) an ophthalmically bioactive agent capable of diffusion through the contact lens and into the post-lens tear film when placed on the eye and (2) associated with the bioactive agent, an ophthalmically compatible polymeric surfactant in... Agent: Miles & Stockbridge PC

20090060982 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: Nutter Mcclennen & Fish LLP

20090060983 - Method and composition for making an orally disintegrating dosage form: The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms.... Agent: Philip S. Johnson Johnson & Johnson

20090060984 - Anionic surfactants lethal to gram-positive bacteria: Disclosed are surfactant compounds and compositions that are antimicrobial. Also provided are polymeric compositions incorporating the surfactant compounds. The polymeric compositions may be used to form antibacterial coatings on surfaces.... Agent: Michael Best & Friedrich LLP

20090060985 - Process for the preparation of plant extracts for treating skin disorders and enhancing healing of wounds: The present invention provides a process for the preparation of Plectranthus amboinicus extracts using a stirring separation method. The present invention also relates to a pharmaceutical composition comprising the Plectranthus amboinicus crude extract and/or extract for treating skin disorders, including enhancing the healing of wounds, especially in diabetic patients.... Agent: Wpat, PC Intellectual Property Attorneys

20090060986 - Transdermal delivery systems: Disclosed are bupivacaine transdermal delivery systems, and related methods.... Agent: Durect Corporation Thomas P. Mccracken

20090060987 - Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions... Agent: Medtronic Spinal And Biologics Attn: Noreen Johnson -IPLegal Department

20090060991 - Glutathione based delivery system: A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded... Agent: Birch Stewart Kolasch & Birch

20090060988 - Nell-1 enhanced bone mineralization: The present invention provides Nell-1 genes and gene products and pharmaceutical compositions comprising the same that promote bone mineralization and osteoblast differentiation. The Nell-1 genes and gene products also represent targets for screening for modulators of bone mineralization and osteoblast differentiation. In addition, Nell-1-associated compounds and compositions can be used... Agent: Squire, Sanders & Dempsey L.L.P.

20090060989 - Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery: The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the... Agent: Wilson Sonsini Goodrich & Rosati

20090060990 - Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery: The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDS) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the... Agent: Wilson Sonsini Goodrich & Rosati

20090060992 - Preparation of magneto-vesicles with dope/ddab layers: Magneto-vesicles with two different surfactants, i.e., Dioleoyl phosphatidylethanolamine (DOPE) and dimethyl dioctadecylammonium bromide (DDAB), were synthesized using size controllable magnetite nanoparticles (Dm=9 nm) as cores. From AFM measurements, the average sizes of vesicles and magneto-vesicles are approximately 316 nm and approximately 311 nm, respectively. These biocompatible magneto-vesicles have very good... Agent: Law Offices Of Brian S Steinberger

20090060993 - Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones: The present invention describes a solid oral dosage form of ubiquinones (e.g., ubidecarenone, coenzyme Q-10, idebenone or mixture thereof), providing on contact with water or body fluids the regulated release of an “in situ” formed oil-in-water emulsion with ubiquinone incorporated in the oil phase. Described formulation demonstrates improved bioavailability.... Agent: Alpharx Inc.

20090060994 - Controlled release azithromycin solid dosages forms: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.... Agent: Howard Eisenberg, Esq.

20090060995 - Dispersible sustained release pharmaceutical compositions: Disclosed herein are pharmaceutical compositions, in particular, dispersible compositions comprising sustained release granules of at least one active pharmaceutical ingredient and at least one release retard hydrophobic polymer formulated with super disintegrant and lubricant, to achieve dispersible and sustained release effect.... Agent: Pharmaceutical Patent Attorneys, LLC

20090060996 - Formulations of clopidogrel bisulphate: This invention relates to pharmaceutical tablet formulations of clopidogrel bisulphate which include glyceryl dibehenate as lubricant. The tablets are found to be very stable and to exhibit suitable dissolution characteristics.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090060997 - Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate: A combination of an anti-androgenic gestagen at a daily dose of from an ovulation-inhibiting dose up to at most twice the ovulation-inhibiting dose and from 0.1 to 10 mg of (6S)-5-methyltetrahydrofolate are used to produce a pharmaceutical preparation for therapeutically treating endometriosis while simultaneously reducing therapy side effects including the... Agent: Striker, Striker & Stenby

20090060998 - Lipid-based dispersions useful for drug delivery: The invention provides lipid-based dispersion comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical... Agent: Viksnins Harris & Padys Pllp

20090060999 - Protein formulation: Comprised in the invention is thus in particular a new pharmaceutical and/or cosmetic formulation of an active enamel substance at a lower total concentration within the formulation, wherein a spatial and/or selective regulation of release of said active enamel substance permits a greater percentage of the active enamel substance to... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20090061000 - Pharmaceutical formulation use 030: An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)—(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions... Agent: Morgan Lewis & Bockius LLP

20090061002 - Calcium phospate based delivery of growth and differentiation factors to compromised bone: Resorbable calciumphosphate (CaP) based compositions comprising growth and differentiation factors (GDF) and their uses in bone regeneration and preventive treatment, in particular of osteoporotic bone, are disclosed.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090061003 - Carriers for drug delivery: The present invention relates to chemically bonded ceramic precursor material of aluminates and silicates exhibiting a controlled release rate and properties that make the material suitable as a carrier material used in drug delivery. According to the invention, this is accomplished by selecting a microstructure based on pre-reacted phases and/or... Agent: Young & Thompson

20090061004 - Leave-in hair styling product with particles for improving hair volume: The present invention relates to a leave-in hair styling product that improves the volume of a hair-do. More specifically, it relates to a leave-in composition in the form of aerosol mousse, pump mousse, gel, spray-gel, aerosol hairspray, pump spray, hair wax, hair styling cream or hair setting lotion. The leave-in... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090061005 - Paliperidone polymorphs: Described herein are novel polymorphic forms of paliperidone, processes for preparing the novel forms and use thereof. Also provided are processes for the preparation of novel polymorphic forms of paliperidone and the use thereof in the preparation of pharmaceutical compositions.... Agent: Cantor Colburn, LLP

20090061001 - Sunscreen aerosol spray: A sunscreen formulation and a method of dispensing the sunscreen formulation is described in which the sunscreen formulation in the form of an emulsion includes one or more sunscreen agents and one or more propellants contained within an aerosol can such that the sunscreen composition is dispensed from the aerosol... Agent: Pearne & Gordon LLP

20090061006 - Layered nanoparticles for sustained release of small molecules: Nanoparticle compositions and methods are disclosed for the sustained release of small molecules, such as pharmaceutical compounds in vivo, for example ligand-lytic peptide conjugates. The construction of the nanoparticles helps to prevent self-aggregation of the molecules, and the consequent loss of effectiveness. The system employs layer-by-layer self-assembly of biocompatible polyelectrolyte... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20090061007 - Pharmaceutical preparation: A pharmaceutical preparation comprises nano-level particles (nanospheres) of a biocompatible polymer having, as held on their surfaces, an NFκB decoy capable of binding to NFκB to inhibit its activity. With penetration of the nanoparticles inside cells, the NFκB decoy may be delivered to an affected site and the NFκB decoy... Agent: Fitch, Even, Tabin & Flannery

20090061008 - Fiber/granule complex for treatment of the gi tract: A method for treating a gastrointestinal (GI) tract including providing a fiber/granule complex made of non-absorbable fibers having granules attached thereto, and ingesting the fiber/granule complex orally, wherein the fiber/granule complex treats materials in the GI tract as it passes through the GI tract, the fiber/granule complex not being substantially... Agent: David Klein Dekel Patent Ltd.

20090061010 - Cancer cell targeting using nanoparticles: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090061009 - Composition and method of treatment of bacterial infections: The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.... Agent: Alpharx Inc.

20090061011 - Compositions and methods for delivery of poorly soluble drugs: Described herein are compositions comprising particles of poorly soluble drugs encapsulated by stabilizers. Further described are pharmaceutical compositions comprising such encapsulated compositions. Also described are methods of making such encapsulated particle compositions, and methods of making the corresponding pharmaceutical compositions. The encapsulated particle compositions described herein allow poorly soluble drugs... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090061013 - Methods of enhancing the quality, nutritive and health values of meat from bovine: The present invention relates to methods of increasing the selenium content in beef by feeding special enriched diets, methods of improving human immune function, such as providing anticancer benefits. The present invention further provides methods for improving the quality of beef meat through a special enhanced diet, wherein organic selenium,... Agent: Mckee, Voorhees & Sease, P.L.C

20090061012 - Shark repelling method and repellent incorporating wax: A method of repelling sharks for limiting their attacking a surfboard user comprises applying a conventional surfboard traction improving solid wax that also incorporates a shark repellent such as a surfactant, a capsaicinoid or a semiochemical in a concentration based on the “Johnson & Baldridge Test”. The extent of application... Agent: Anthony Drew

20090061014 - Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme: Peptides and conjugates thereof comprising one or more bioactive agents which can be coupled to a tissue via a transglutaminase and related methods.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20090061015 - Regulation of protein activity by reversible acetylation: This invention discloses the first cellular acetylated substrate protein of SIRT3, Acetyl-CoA synthetase 2 (AceCS2), which is a mitochondrial matrix protein. AceCS2 is reversibly acetylated at lysine 642 (Lys642) in the active site of the enzyme. The mitochondrial sirtuin SIRT3 interacts with AceCS2 and deacetylates Lys642 both in vitro and... Agent: Townsend And Townsend And Crew, LLP

20090061016 - Seawater based dietary supplement product for energy and electrolyte replacement: A seawater based dietary supplement or functional food beverage product is revealed with enhanced energy profile, antioxidant properties, flavor and health characteristics. Seawater sources are combined with extracts of green or white tea, grape seed extract, d-ribose, extract of the roots or rhizomes of Eleuthero, extracts of the fruit of... Agent: Arthur G. Schaier Carmody & Torrance LLP

20090061019 - Disinfectant compositions and methods of use thereof: The present invention discloses a highly potent, non-toxic, disinfectant that can be used for a wide breadth of applications. The disinfectant comprises hydrogen peroxide (H2O2), orange terpene oil, orange valencia oil, a non-ionic emulsifier (polysorbate 80), and water (H2O). Applications of the disinfectant include, but are not limited to, uses... Agent: David S. Resnick

20090061017 - Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions: The present invention relates to shelf stable and/or less corrosive peroxycarboxylic acid antimicrobial compositions, including ready-to-use compositions. Shelf stable compositions can include defined ratios of hydrogen peroxide to peroxycarboxylic acid and/or hydrogen peroxide to protonated carboxylic acid, but need not include strong acid. Reduced corrosion compositions can include carboxylic acid... Agent: Merchant & Gould PC

20090061018 - Tooth brush sanitation methodology: The methodology includes providing a portable, hand-held spray container to user for spraying a toothbrush with an effective amount of a solution containing: (a) water; (b) a flavoring additive; and, (c) about 0.5% to about 30% by weight of at least one antibacterial component. The antibacterial component may be selected... Agent: Stuart Dejonge

20090061020 - Brimonidine compositions for treating erythema: The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a... Agent: Hoffmann & Baron, LLP

20090061021 - Combinations of imazalil and silver compounds: The present invention relates to combinations of imazalil, or a salt thereof, and silver compounds which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more silver salts selected from silver acetate, silver... Agent: Philip S. Johnson Johnson & Johnson

20090061022 - Pharmaceutical composition comprising arsenite for the treatment of malignancy: A method for using sodium meta-arsenite (AsO2−) to suppress growing of human cancer cells is provided to find a method of curing human cancers. Effects of sodium-meta arsenite (AsO2−) on various human cancer cells are investigated via in vitro cytotoxic activity and in vivo anticancer activity against nude mice. For... Agent: Sang Bong Lee (attn: Je Ok Lee)

20090061023 - Nutritional supplement: A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to... Agent: Docket Clerk

20090061024 - Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect: Provided herein are compositions, combinations, and methods comprising NMDA antagonists including, but not limited to, NMDA glutamate receptor antagonists such as [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1-(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof, which are effective in reducing the amount of anesthetic required to maintain anesthesia (i.e. to achieve an anesthetic-sparing effect).... Agent: Wyeth Patent Law Group

20090061027 - Composition for the prevention and treatment of common cold diseases: The invention relates to the use of Cistus for producing a composition for the prophylaxis and/or treatment of common cold diseases. In particular, the composition can be used for the prophylaxis and/or treatment of the symptoms of a head cold.... Agent: Kilyk & Bowersox, P.l.l.c.

20090061025 - Compositions and methods for treating demodex infestations: Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular Demodex infestations... Agent: Wilson Sonsini Goodrich & Rosati

20090061026 - Nutraceutic preparation in powder form containing free plant sterols: The present invention relates to a nutraceutical preparation containing, in the same unit dose, a dried powder comprising free plant sterols in the global quantity of 0.5 to 3.0 g. The preparation preferably also contains red yeast rice, soluble natural fibres and natural antioxidant compounds, the latter generally being carried... Agent: Notaro & Michalos P.C.

20090061028 - Pesticidal/ovicidal composition and pesticidal/ovicidal method: A pesticidal/ovicidal composition comprising: (a) 50-97.9 parts by mass of a triglyceride containing not less than 50% of oleic acid as a fatty acid component; (b) 0.1-20 parts by mass of a cationic surface active agent; and (c) 2-30 parts by mass of a glycerin derivative, and a pesticidal/ovicidal method... Agent: Buchanan, Ingersoll & Rooney PC

20090061029 - Nighttime water: Exemplary embodiments include a composition which can be added to drinking water and consumed to promote sleep. Embodiments may combine extracts of chamomile, lavender, poppy, valerian root, sage, ginko, and/or peppermint. The composition may be found on its own and added to drinking water by the end user. Alternatively, the... Agent: Standley Law Group LLP

20090061030 - Cosmetic material containing swee pea extract: A cosmetic material, cell growth promoting agent, elastase activity inhibiting agent and anti-aging agent containing sweet pea extract, formulated with the aim of preventing or slowing aging.... Agent: Knobbe Martens Olson & Bear LLP

20090061031 - Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus: The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein... Agent: Klauber & Jackson